var title_f23_46_24288="Atopic derm infantile PI";
var content_f23_46_24288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis in infants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 419px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGjAUcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5mkRT8xVTn2qPYv8AdX8qmfrUZFUWN2KOij8qcMDpRilxQAopw6U3FKBTAUCngVHTgaAJAgNSCMU2L5mxVooAuaRSIfKp4hGKUOB1NSxkMRimPQks7VdwdxlR2rbsoSTkjr0+lVraAYXPJrZsoxkY7VLNIRuX7WIdhV+NMe5pLVQBkir1uqFhxWLZ0qJEkTMQSKv2sGTyOlTJHknavNXLeLBHB9z2qGzZRHQptXkfL71J5OR8nSrAXAwRxTkAOQKlspQIEjVW6fjTXgDEgjI61c8vAycHNKYiR7UrlOBmizJUAdM+nSnSWZGeM1fgjYkDGOxzVp4h6UXJcbGC1sdoGOnrUP2fHUbSO4610DwgjIA4qoUBzlaBqKsYMtqcMduSRVWSLaDgV0skakDYPrVC4t8HIFNMnkOZliAPvVWaEPwwrpbu3U/w1Rmt1UZA/OrTuZyjY5S+sV2lWQMp6ZFcTq1q1tcFSu1e2BXqk8QYbeprnfEOmG5tmwMSKMjitYS6M5qsLq6PPTSq2DmlkQo5BBBHY0gGT0rU5DQgm3RnPbpXZeD7NMK0/wDEd3NcPEQGArvPO+yaZFKv93FRPax0UN7sz9dm87UGCnI3cU2JdxAXoKz4pTLMXNbWnx8ZIqXojWPvyLtrD04q+kPyg44otI+lasSAgVzyZ2xjoYE0RU9MZorS1GDa3HT1ooTIlDU8ikHWo+tSyCo+9dh5IYpQKUUvagQ3FLS0YpgMoFLilApAS25+cVfc/u6z4uDmrgbK4plIrBS8mBWlYwEv06d6baRBQZD+FX7BDyTmgcUaVvGBwBxWxZRjG0c5rNtRzkdq3tOiLc1lNnXSiXYIflGelaVvAABmq0KgH5hxWtaRkqCfyrBs61Gw5IOME4z6VbgjMYAIp0ce3r61YUbjkjntUNmyiN28cdaWMdj1NShGPbFPjQlueSKCkhghOwFuTT4k5O84zUxU/wD6u9N2AcknmlYW4iw4BPJpWBUdeKcGAAwaSSLenU+xpitrqNVQo68elIVHHy8+9PEXydefWlClSM7iD3oE0VvLAJwoqCe3LNwMGtEqCCO9NaMqORigVzFmhGBntVC6gAGMA5rcnQnOOuaz5ozuoTsDjc56aPZJwOKr3kQPzAc1r3UW7NZ0yHoa1izmnGx5p4t0o21z9pjH7qTrjsa55RzXqur2SXlq8TDgjAPoa8zvLWS0uHikBDKcV0xdzgqx5XcjhGWJPTrXSS34uNMt4VPI6iubQkJWjo0ZcknoKbVyYSa2LtmmGI966TTovlArFt1/f7ccCujshtHpxWVRnXQRp2qDjI+laEajt+VUIMkZrQt1JI+lcsjviEtv5i8jNFaCphelFQDPn96YBT3PNNr0TwgHFKelAo7UAJ3ozS4ooATtSUGimBJH16VODyKhi5qdB84zQNGnAv7se9XoRsQY5NV7Fd5AzxV2VRGRSNkjRsBk+tdRajy4xtGTXPaUoKg8V01rg8YrCbO2ii3Am4gY5Peta3QqoGKr2cS/e9K1YhkAdjWDOtIUA+XkjmpYE7461JhduO1SxgYXFLQvWwpA4pDhMmp8KW6ZNBjQkk0xLzIWywAHSnHJTjBqZtowKQbdxAHFFhlYttTnr61LGcjnnIzVkxI2BgdM0rxKqBgPyoE2mUEVixz3qQgoevan7lGCQck0kpyRwMUA1camWAB7U2UnGBU4AVSvY9DSYwvIzmixJm3CHbuPUVVkXK571pzgBTxVRkDducVJXQxrhcN0rLu0xkgVv3Iwc4HNZV7tIOBWkTCaMRsB9pGQetc34x0oz2wuYly0fU98V1MgA5b1on2NGQygxuMMD3raLsck4J6M8bbOdtdPpNukenrIT87HpWdqOn/ZdWeNcmPdlD6itWD5YzjgVs3ocsI2eotoczseOtdBabmGBXP2P+sJ45NdNYj5OKxqHZQRpW/yr71o2mcjiqUIHGetatnyfauZnckWecYoqVCu08UUkhM+dH602lakr0DwhRS44pBS9qYBSHrS0h6UAMNHeilFAieEdanHUDvUERxU0HzTr60FI39Jj4BPSrV0nzjA6U3T/lQZ6VZxmUZ5qTdLQ0dKAABrqtOTzHA7fSucsYwqr6102msEGT1rGep2UjbtYQq45qwuc4zgCqcMrsMZGKtRFj94cCsXodcVcuQAMoDZqz5eHXB4xVRWOQFFWfMwwxkmoLsPB+c46U7nPNKseRuGc0ijD464/SqHoSmP061IsIODigsCMD05qaMrt5znHHNMzkRlQoBwfSnMPkwc4bpU4VWHuegoaIgDPAFFiW0ZbRMJACRinTR4Xg8GrU0YJ3Z5Wq7/ADDGaTNE7kQUeX8zdKcmG4pdoxjOKEXnGcCmJoguQCNuc4qnJGMDJxzVqfG/rzUUvzDjr3qQZn3CA5B7Vj3ygI1bVzyT7isS/PBqoozkjHk5BHanS4+ygYBpNmXPoaSc4jK44A5FbI5ZHGauA044GR0pgX9zzTbgl7l884bip5hthGfStdjntq2Q2I/e11Onr8lcxp4OSa6myG2NeKzqHRQRpxpucA8CtK2XGFHTNUbYFuTV6IFcYNcrO5ItsOODxRTQCR2xRTtcl2Pnh+tNFOcdaaOtegeCPGKSjpR1FACmkGME96CaRQTkCgQhOKF60hoXk0ATLVqwXdMKqAcVoaUP3mR1BoKW50douExVuJgJAeeKpwSYX61btRuc8HNSzqjqa0AJI9MZrWs9zMME1UtoCeevvW1p0QVgWFYSZ2Uo6mnZRE4yce1asEYXANUoWVRkCriz/L15rI7VFJFpUXkjrSsjId3XNQRTjcNx+tW/tKbQeKVhPQFyrDnpUjDPJOPU1GGDBiOoqN5drfNS2J9CcyYG31p0cnGCOPWqRkJJP6VYiJK/L0oTL5dDTiJKDJGfekcvlRkcVEr425HvmnSTbcE96oxaGM/zEH1qMgEgdKguJlUA5Jqqk7ySY9KTLjHQnlbDn0pckdSce1QvKC/XtT45V9uaBshk5Yc9+lLkbSOlNuNxbI5HtVbziOCeBzRYUitePjvkVh6i4OFOea2b9wwLAADrWBcnLgk9elXBGFV6EQjwPc1R1aURxnn5sYraICx5J6VzniSRFh3A/MeDWiOZs5mBd8rE+tTXz/Lj8Kba4C570kvzygVq9zJLQsafGNq/WuitBhfbtWNZKAwz07VvW4HFY1Dqoqxp22Sgq/GQpGeTVG3HYHFaEeARk1zs7EKzkcDpRTsDP0opiZ87t1pBzSt1pBXefPC0lKab2oELSUvbmimA00qDmkNOTrQBJ2rS0wlVzxg1ndqs2bcGgqO50Fu248Vt6VHubGOawdNBbv14rtdDsyMdves5ux20I8xr2MQFscgg1ehOGHBxV6G1UwDscAGmyQLHjJFc8j0aS1GGdYlyxwKz73VZo3xEhPGfqKt3USsCFIz6mqV/5UGh3S26f6SYyN3U/hTpQU3Zuwq9aUI3ijNh8QySS4Z2PONqitePV4YzH9onnhXk5deBz3rgxHM+nSPbZEwXCjoc1oJD9jtQq3kt4jxo7GZNpRyPmX3APeuz6vDY8z65V3PR4rh127XWRG/iU8YqaRyPeue8OoU0fTpFPzSkp5fqOxraf93Jg9utclWn7N2Z6OHre1jcnQknJFaEBGM1RiJZhirMav2GOxrBHTcutIQoxUE8vKjtUbl1YbicUydwV7ZxT8iWkgkIYkU1Qq4PQ1ASVTIPJ96x9W1WKxcI/myTMMhU9K0jTctjOVSMNzfaMZzTUIBxniuOk1yVIjKWkXecBXGdv1qex15GYCcgA9CpzVSpyjuhU68J7M615ECbcVSm2K5wOahSdZl3xtlW6VKFLjmoNWjJvpMAjkA9qx5TkAe9bWoxFeOv9KxbhSGA5xVROaqieVwISR6YrjvE0wZkVSeT09K6eYkqV/hxXEa0zPfBP7tax3OSeiEiwsYqSBdz5pignCirlvFxk8U2xRRPbgCQVtW+CKx7cZYketbEPAFZSOmmaVsRjHer6FTg1mW7EEDrxVtHIOf0rI6osuEjk5BFFU3kwnPWikDPBW6mm5/WlfrTa7z54Umk7UpoA4oEAxnnpTmGM4OaaKcOnvTAaRTkHNIa0dCtDe6lDDjILc/Shuw0ruyLum+Hr2/h8xFCJ2Lnr9KiutMuNMujHcgdOxr0mcf2dZxsF+QYGB2rj/FVyLjUAV5BA6VnGbbOudGMI+YaImSD2r0TRIzhGPQVwuirhF7V2dhOUQYPAqKjOjDqyOnu7uOOHYOtZLzSyyDLcUi5mbJzVqO3y47D3rGR2UkluLDuAyeamLoQAYRn605Y9vQ0xy24YFRdo6OVMabOzlP763ULnn1pL600+YKFtgVVdvzc04hyQMU9Y+hI5q1VklYylh4N3sPs1ESqkEYUAYGB0qdEO4luc0sIOBsHJqS7ItoTJKduOnvSb5haR0Q9WVMZOPep1u0J+bmsKCSW7+YZCmrq2zhehqb2DkuajSJIuVPSqtyN447VVWVoWw/Sp5WwAw6Gi/UpJrQkiEfybxlF6iuA16SSTxDdSMpAHCFhgdOMV2rPnnOKjYxN8s0auD1DDOa6qNfkVrHJiML7V3vqeYzrcQ3Mey+luY5Yd06vHtEb5+6PUY71o+FrRbu/vImb7se8E9A1dffaTp9z8xhIz2DcU2z0uys8m1UIW+971q68eWz1OaODqKV9iPTgUj3JuLKcMM9feteJyy8d6ijVAOAtWbd40ODwa4up6eqViCa3LHJHHpWBqoCFj029BXWXDKi4znNczrIUA+pppmck2jJlcsBn061wurOp1VwPXrXcyEGP0wPzrz3UZg2rSYHG6t4bnnVXoatkMy5IzWk6YjAx1qlpoDPntWsQHdABSk9TSGw2GPYoJq6h4BprrvlSJeg61prbokWT2rKTNoogjLAA+lWYmO3moACThBUyxlcD86g1UhzguoPSip4wuPaipsXdngj9aQU5+tIBzXoHgARRSsCODSDjFMQtL2pD1pw5GKAGHrXcfCe2jufELebyEjziuJOOldb8Lb1bXxbAjkBbgGLPv2qZ/CzWi7TVz1HxfDDBo6rGnzOCT6mvILoEz5PY969b8cOXuLe1GdyxnOPrXkuoqUu2HoaypHdidkbWin7p9+a6u0IJHpXIaQwEYBxnP411GnsGwMilMqgdBbOFUZ61bWfc5BFUolAQE8jrViONuGrGTO+CuTiQjoangjDcseveoYlAIHc8VbRMcHgVm2b2ZIqjOQMgVJGi9hyfWiIBUY57YFWLZUz8wzjnNLcT03LCiK1hMkxAULnpWMsMmrXBeYYiHKJUmsX8EsfkWrNM5IyEGRVmystRubcJBZTLkclRWvLJ7I5HNLVsntrSOHAGMVqxx2/kkMCH7Vh2Ph7xDZOTKJ5oCchXTJX6Gpp5Z7f5ZonR/wDaGKmUJRew41IzW4upWfmIxUVWtY/OtirHDocVUh1TVHvCkttGttngg5LCtTaEutyg4cZIqVozRPQoSxbQR3qsQWB3A57GtCdSznbzzUXlnnFCbRvZNFABg2D0p4TIOO9SujBjioxI0ZIYcU7jsgWLc23PWpjFtHvUke11BFK5Zuh6UIwnuRSDIBxWJrSArxng1txnkhuKxta4Dj0HFWjNvoc5qLiO3Zt2cDgV53KSb5z3zXr8WjxXUUMkqlvlztzwahuPDumT7lNsik/xAcitY1FHc454aU9mcZpP+r3YrXVgibsjJ6CoJ7D+zrh7fO4L90n0p8Q+0X0UQHC9aG76kJcujNrSbPpLJ1PNWbphJI0aYwKViIowueg7VBAcknPNYNnSl0ImjnU/LjHoajS6ZZRHN8rkcZ6VozNiI9zWBqHzn+R9KcXfRg4djbWQY5OfpRXORak9s3l3GSnaTHBop8rFc8wem0rHmmk12njCk0YzTakjUsQPU0ANHFKOnFad/p/2O0idyC8gzj0rMP3cinYVwxjk1d0O4+y6xZT5x5cytn8az80qHDA+hzQC01PoHXFM/iJGTDBoNwryjXk26lKG4IY16toTi6vrSaTndbr/ACrzPxbGU1m5wOA5rCnuepX1gN0xgjfhxXT6a+FB6k1yVs2Nv97v7102kn5TVVERh3qdXakCMcZB9avH7vX8qybckqgJxVxHODg/j7Vys9SCRdiPORnNPEjM/P5VHbYCsJCRkfLUsDDzFLEBCcE+lZG+hLLOtuhlmbaqdc96saHo+o+J5/lDW9kPXj86raNZP4m15bdSPsUDZYgcHFezaXaIkS2tonlW8fDEd/auyjSXxM8rG4zk9yG5n6H4a0vSIVS3thdXA6swzg10kC3gHyiKIHoB2qxEqwptRQoA7d6mjYtnjFdNjxXNyd2V1F4ORMh+oqvewpdIyahZRTLjqBWkBikYYyaVhqbR5zrfhAbWuNDb3aBv6Vy0b7XZJFZZ14ZWHIr2WeEZ3w/LKPTvXIeM9ETULZtSsk23kI/eKBjeKxq0VLVbndhsW0+WT0OIC7t2cktVd1MZKjmp7a5VkBxjsfrTJnQk+v04riPchqUWVic9s02aP5c1bJAUdz1FRuwKjPGaDS7KERdXJzwO1WVkyCe/akZVEZqIMqsOapGVTUc8oCndwawNSkyzZPBNbF/Kgi46/wBawpl825ijzguwzWsTlnobcZZoVjhGAqjJ9OKZ9llt3jnJLxtwQe3vVqSP7NAIxzk4J9a1bhV3QQEfdG5qzZTueb+JmB1cKPvBORVHQ2/0mSRuucA1X1zU47zxHfSRMCivsGPbijSpgN3ua35bROPmvI6S4bdFgVHbny2wfTOaLcFosk9e1OKEsc+lYs6EPmctjB4rPvYyw9wKvKRtIPUVAxDYyOnBpIrZmKsCzRskgJwc4z0oq3cxCOYMo+Vic0VqmzSyZ5O9Mpz9TTRXUfPjlXcwA71rGGOyhG/bLKegHQGqVjCzyHau4gZFdV4Z0E39vc/aUIdx+6LcAGriiZO2rOZeK6uYmkwzpH1PpVIjjmvQF0xtO0iZXwc5DccZrgpDuY4oaFF3I8cUrLtYqSD9KMU2kM9X8L67Gvhy1lzm4hHlBe5Iqtrmmu+nm5mYGVmLFR1Ga5/4fW4nu5S54XG0ds+tenzaek1oykjO09e/FYSaiz06alWgmzyiE4kC44rqtLGEQg43CuZukMN5x2aun0n5oiO+MiqnsTSVpNHTWrAhc9R0qZZ1DjABBODmqUR2hSp7cinIASPX3rlkj1aT7mosm5dv8P15qLUbgQ2LFSA5G0e5qAzR28O+VgMVr+CvC9/47ut4JtdFgky8x6uw/hWlCm5MdfERpRbZ3nw70+PS/DcMpws122AxP616VaG3igRIizBR1x1qlo3h+x0u1iht4ywj6M53GtXysDjpXoKyVj5ic3N3FVlYDgj60/fGByQMetVbu5jsrWS4fJCdh/Koo0kukV5ztUjOwf1otcnzL6PG/wB1gTSuuRVX7Mg+4SpqWCRm3RsfmXp70rWFuKFHcVSu4hFMsoHyH5XHrWgeKrXwzA2PTNMS3PGvE2m/2b4ku7dCFjdvOjGOoNZ/3kLdPeun+JYxqGnTngvGUJ+lcas7EsCfoMVwV1yzPpsDJzpJserFJMMc1ZlT5RnpVQqX5J+gqyhPlAE5rJI6ptFacYQDp9KpyOFXNT3Ug3be1Z8r4OG61SJktCK+lzsHY81VgRpNQTaSCBmknkDTE+gq3oCebcTSMOBhQa1ekTj3mjWkST9yXBK7gfrTfEd29jp0pVv9MnUhf9ketXr6SPfCgOAPmbPauP1a6a+v5JnJKnhfYUoruKpLseWwu9vqEkcnViTz61t6TKWlxnvVDxlCINSEicZGaXQ5d0ikGup6q55sfdnynoVmD5Q78VbVP3Z9TVCwb90Oc5FaSsMe9ccj0oFQpjIqpMuxwy52963IoQ2cjg1GdP8ANjIFSmW0Y8qq8YIPXqPSii7gmtHw6naehoq0TzSWh4y/JoRSSAKc1beh6Qbhkkkx5Z5wK7keE3Y3PCmmPHbmZgCTztI7Vv2Gq2r6i1iJAUZcxkH7relYev6rFZWEdpZyAyEZLL29jXJ213Lb3SXCNiQNkE1pexly82rO18Z6m0FuYSvzSgggdveuS8O2A1Gd4WAJI+X1zUOs382oXjSzEZPYdKu+EhMmsxGIHcuXI6ZwKW7HbliJr2lizgWRFIydpB7EVz9eha4ragrkpguOF64auDuImhlZHHIODUjhK6LWiarPpN2JocEHhlPQiu7/AOFh2xtTm1l87bjGRj8680b2oqXBS3OinWnTVos2G1F729ZnAVScgCuz0OTKKSeoxXnFs2yZD6Gu30OcqAM9OOaU1obYeblLU7WBWeIkYp06FGTnk/pUNhIRFk/hVqUhot+DuHeuSR68HZHM6vPLd30VnCSWdwgHuTivrXwhpMeg+HrHToECrCg3e7Ecn86+SfDJEvjvSFl5BvI85/3q+z45BkZGK64K0TxsZUcp2EkYpnAznoB60gEjkFzj/ZFQahKYzHKvCocsPUVejcOFI5B71Zx2MXxT5n9lKyqdiTIz/TNaVvzECTwQMVYlSOaJ4po90bDawPeqdnaS2kZjhfzYQflVuGA9M96V7Dauixzmi2G64dh0UY/GobiSaNkUR4Zzgc9PerFunlBh17n3p3JSsPYDPFQXTBYH3elSFxyT0qhqEgwEzgtz9BTEtzzb4kyb9Q0yFSPkRmP0rjiuCSQN2eua2vEt19v1q7uVJ8uLEMfoQOv61jFt5G7jH6152Id5n0+Ai40kIzsMZwBUkcoHzbvwqnITwG4IojX5jzx2rNanZJIJ8sSccVn3BwD0zWhM27jtWbekBSQfpVpGM5aGdI+0n3rd8P8AlxQIJXCF23En9KwoLd727hiT+I4J9B3rcu7QxHCD5BxWknZHJBOTuibVptqSydSwwtYEYXp1qxM7BvLdsjsDUUK4bFPoRUbb1OJ8f2+JIpAOCK5/w/N5dxtJ716B4rsftWmsVGXTn8K8yjJtrwHpg810Qd42OCsuSfMep6fKDGPWtm1Ut1FchotyJApB4IrrrGZdmCa5qisd9GXMjThjJTgZq5DEFXJJBPvUNu4AHPFOMwz04H61mjoYXUKTJsZQR6GipZGzGCp5op2uSfN9uiyTbX3YIPTsa249VFlavFCMyY+V/Sse3GJAc4qWWNSS245HQetegkfPvUhyZZC8mSScmro0q4bTXvVU+QjBScdzW94Y8K3N9cwyyr5dq2DuPQ+1ejvpUUWmtZiNRbn5HXt7NWijcxnVUXY8RsbV7y6SGP7zHFd3dafHayQzRALNsEZx3KjB/OpPDvh6bTdWupZkyi5VGPTB71Pfo0mqGHOSCBkVL0RMp3dkT6XYxzHzJnGXJZB6EDpXnfiiaCfU3e2DAH7wIxzXY+Lr+KxsY7O23Au28Nn7vrXO6b4dnv4mmlR1Un5Wxw3407aWQ6envM5Y9aOlWdQtmtLuSFxhlPSqtQbC5ya6rw/ckgZPXr9a5UCtLRpjHchezUpbGlOXLI9OsJv3aqx4rZyGQDAHGa5jTJAQm8gjpW4p4wCSPrXHNWZ7FKV0clDP/Z/ie1uc8Q3KOSPQMK+2LGWO4top0IKSIGB+or4s8UWWybzIwdjjrX0h8C/Eqa94Ojt5HH2ywxDIvfbjhq64O6PLxcbSuej3EaywMvc1V06f7PiCYAIOFb09jVpV565qpqFnJLmS3ZRKB91hkN7GqscqZq4XrxUc8yWse4/MzHCr3JrnotZNqjRTW1wLlfuweWW3/wC6w4x9a1bOKSST7VdqEkYfLGDkRj/GpK21ZYt42XLSndM5yx/pUisBvY9OlNlkEcbO3QCsy61OKC3+Z0j4yWkYCmTZsvTyRxplvwHrXB+Ndf8AsSPb2zA3koxxzsWq+ueKzLvj0vM0nQzH7ifT1rhXdjcO8rtLK5yzN1NZVaygrI9DCYOU3zTWhbglQWWwjcRnt1PeshyQ52DANW1cKOmOfWqcrHzCeorgk76nu00o7CSjvUbHaAMc05m4OeTUByWxQi29NRXyFLd6y7ts/LnPPNaV0WEexcD3rHupFjV3c4VV3E1tBHJWnoTaUzfa5DburXEfPl552mteS8LJiSOTf6YrxseIrq311760kKgtyv8AeX0Ner6JrdtrVn9ot8jHDK3UGtqlNrU4aGKveJHKpeTewxx09KVUGc4qS45c1Lbx5H4VkaXu7siuIA8TDGQwwa8p8WaU1neMVB2E5BFewY+XBrE1vTo723dHHzdjVwnysitT54nm3h2/8mURyH6V6Hp04IUjBHavNNW0uawuGyCADwa2fDetbGEU7YYdM1pUjzK6OehUdN8sj1G2mOPrVkn34rAsr9XVSCCK0BcBlb5sZrksz04yTNBX+Q80Vnfaig+9RVJg7HiNuhJwBnNacNzFCYHjt1ZkIL7+Qfb6Vlr8pCq3XuKk3OV29h3Femj55nuGgXVvcaYjw7QqLiREGAD6/rVqRSsLb2LsvysAeqnvXmXgTXP7LuTDdyO0E4CgHgDJ7V6U8kgRsREugAAJ+8hrVO6OCpDlkZt4wtbfAyzRpgZ/iWuesTuuJZXI+UhgxrR126WSQJGQVVRsIOc+xrntYke00GWQPtMuFGPTNZN3l6FwVzDKyeIPEHlKHZC5wo/hFdhq15FommRqg3pImxoi3KOB1xWP4Gsmt7a5vJj5Ujr+7djjBHPU+tYOqXh1fU5HSHbPKwwFOR05q1ojZrmfkjEv90szSkliepPNUzXpbeFFj8NS3bxstx5WWQ9AfUV5s4wxrOUbM0jJS2G1LbuUnRs9DUeOacBjmpLR2umXRUrjhvX1rqLS4/dhXBBIrltHhW5tI2744rctbh4JFW6XhRgHFYzimehSk0jbktFurXZMMqensazvD2pal4G8Qpf2YLRn5ZY+0iehq9bvvkURyHHv0rQkRJUKSKGU+orNScGdE4RqqzPoHwh4r07xPpqXWmTq5x88X8aH0IroFyec18li2utIvRe6FdTWs687kOPzHevRfDnxh1OKNIdbsIrojjzoW8tj9R0rdVIs82phJxfu6nuHNSIc9egrzu1+KWnzjJtLhD6HB/WqOseP7i7hMVjF9nVhguTlse1KVWK3YU8FWm7KJq+PvEDEiwsJduDmWRe3tXHpLDJBI15I88pOPnJOB6isua4YAs5yT196h8/92fU1xyqtu57lHCRpwUUWrm7EcfygAdBiqCTfvMnnI702SQFeagBJYADmsr3Z0cqSLocHJIH41Wmb25p4BK+9IIcjB5oGtCBiVAAHWmScDgVZdADx1qrPnoO1NIUpFe6lIG0HOa4/xvem10wRI2JJzg+u0V1ki4Vmf5VAJJ9q8l8Uan/aeqySKT5KfLH9BXXRjdnlYypyxt3Mck+la2iatPpF3HPA5KA/MmeGHoayGyeT0oDdMGutq+jPJTad0ewaNrVtqsKyKwSQ8GMnkV0dpyK8CtZ5La4WaF9rocg13ugePBDHHFqMRZs48xPT3rmnRe6O6liVtI9DnAyfQ1SnA3ADqKZbanbak5+yTLKFGTtPT61Jj5icdKwtZnbdNaGRf2UF6jLKgyeM+lcTrPhmaBzJbAkdRivRbmLHK9e9VypK4IzVxnymM6Sluef6XqN5Yny7mJig7iumg1qFgMHH1FaUlnFIeY15qFtOgHIiBP0obUt0KKnDRMibU42PDcdsUUrWSY/1Q/KiptEv2kzyx9quVRtyjocVIGx0P4VW4L4I4zUh+9gV3Jnkl63uWNxEZAZDH9xfSvRdB8USX1jIhGy5RsIB6eleYwuy5249M1bsbo2dzDKgI2nLc9aq7toZ1IKSPQo4VuJlUNkO2Rz0Peub8aOLnUrSytj8vA29gc11lnNaxaQL9tsazAsrdNrdq5Dw08N5e3t3djzJ1O9ST6elKMbIyhpdlzxhfC002PTolQ741WTnlSO4+tS+AtIEkbXt3GjpGQygnBxXLzXP9q64kkuAu4bsf3RXU6r4oh0yA2+nbFlj4BUZDL71aet2VJNR5UdF4s1m3ttHltY5IykicFWzj2rxd8bzVm8vZ76ZnkYnceF7Cr+leH7u+cZQoh7kVnKV3dmlKlyqyMmKJ5ZAkalmPQCt+18Nzm2aeUcgZ2+1dvonhmCxjB8sFyOXI5rce0UJsAGD1rF1Ox2Qo9WcT4WUHMRHK9BXWGySSMhhlT19qwbC2+xa9JER8p5Wu4t4cgFRnjmomzopq2hyz2k9iS0OZY/7vcCr1jfxuoXHOe5relsGZS8Az3K/4VSn06C65YGKcdGXg59xUOV9zaN1sSwSJN8pAB9PUVHd6PEX86B8E/w+pql9nu7LDToXj/vrzV23vVJHzbqz1Wx0RtLcihZrZisqsD79K0bedSAd4NSRypMuCMrjnNC2cAyQuCfQ1DszaN4j2lUrjORUJkOcZzj0qZbSHaPvc+9TRrHEBtUZ6VNka8zIEt5ZVBC7R6mpBbCE/e3E96tGQjGehqGVwSMUbBvuO2YUe9MHFOL7R14poYMcDk0EylYZKcDjr7VB5TOdx4Bq6sIzl/wFOnjY4UYBPQVSMJTMDWrR7yynto2Kq67WdeoFeS654eu9LYkqZIezgfzr6AFmqxBT0/nWXqGnxSoyuoYEd+a6KdRwOGtSVXV7nz3xjBFR4AOK9F8Q+DcO0tgNrddh6GuGvLOa0kKTxMjjsRXXGalsedOnKG5UwcnAqQg4FJjAxnrSkfuxz71RmS2l3cWjFraV4XPUocZrrtN8dXMWyO8iWVQOXHDGuJzxRk1MoKW5cKkobM9Sh8ZaZcoplZoWJxhhWxFe2ky/up4m47MK8WbBxSozLkBiue4OKydBPY6I4uS3Patu4HaQfbNIF28nAHvXjCXt0hBW4lGOB8xpz396wAa6lP8AwM1PsH3L+trseyvJCI97yIFHHUUV4r58x3gyvg84LGil9X8xfW/IaOp4Oc0/nJPr1pqjk08AlgOefSuhHKKvHOeKl3kYJ6gVG/y/e6VBNKTgL0p3sIvz6rO+n/YmdjCG3AE9KfFqRstO8m2YeZJ94+nbFY+STzUlvBJcSiOJSzHoBS5hcokUjqTsJBPHFaum6Fe6g4LKY4z/ABN1P0rqvDHhIArLcjdIegPQV6DpmjJG4JUcetYyqW2Oulh76yOT0DwZFAFd497+rc12FtpCwY2KK3oLZVXAXpU4iADYFYuTZ0KCWxiNbhSBjAxVSRCWwo5FbN4gCZFUY4/m96RVjnNcsSpt7qJf3kZJbHcVp6VcgEA1rfZt6hiuVB5z6VkXVm1jc/KP3Tcr7e1Ve6BKzOltvLdAVGDUlzpaXCgt8r44daztNn2oAa3bWbcBkjFZsuz6GHJp93bttAEyew/pVKeztZ2O6IxSdCRwa7RCpbIHzU+W0gn/ANbGrfWp9C1O26OAFlLASIp9yH1qZEuFGCufoa62bQLZvus6/Q03/hH1CYWVvqaGmaxqxOa/fkDcmOKerSKDmM1unROQPOc/hUseiqGyXZgOvNTymntF3OeDORyp+mKclvI7ZxgV1sOlQKo+XJ9zmpDbRxk7VH4UcpDq9jmotPZuqsx9+lW47ARgFiFHoK1Xbaxqlc3AQhSck9FHeiyRLk5FdlhiUNt57Z60kEDM5duCensKmjgZn3TcnsOwq2E2IWNC1JehVeMLx6VTmjznNXptxyR+VVJWKpnpV3JsZV5ECCDXOanpdvdxskqBwfUV1jqXB4/Oqr2uckDNNSE4J7nk+r+DmVi1mxx/cb/GuVurWa1k8q4RkI9RXvUthu7VlatoMF3EVniDA9K3jWfU5KmFT1joeIsv40h4rpvEvhubS2MkYMlvnr3WubPHJrpTTV0cMouLsyMnmkJ5680pAPNIw6CmIQ9DTTwafjGfWm7evagQ0dee9FPBwc4/OigCVBkk1L9zkEg/yq0tg/2Xzhghn2AZ5zXUeJdL0zSfDVrEWWTUnUSNhuRnsR7UktBuSTscNM5Y4JqFqU+9GCeBUjH20L3EyxxjLNxXqPhDwytvHvkUGQ9WrI8C6HlhPKnzt69hXrmnWQjCgADisKk+iOyhSt7zG2GnKgXCitZbbYOnAqe2hHGe1WAoLHisTqK6Jhc1FISBVxwApA/Gq8oXZmkUrGXeH9ySfWoreLc3I4NWrhN8TDuKW0QDrTAsW8Q2FSODVW8tRKpVuorRUdCKbJhjzwaaJOdiiaGXBrXtM4FRXMPzbsU+2DK4FKSKVzRjYgYzVpJOefyqmDjHHNWoyMY9alDZaVzkAVNuGRVUEk8ZxUsSknmhsEiVmB5GBTSwxgCpPLCjNRF8npxU3GPLDGaqzzBVPIpZGxnnC9zVN8S58v8A76NK40iG4mduFHJptrbbX8xxuc96uQwhck9T1NWPlUbulCQ3K2iK+3ByRxUTHc3sKdLJk+1REfKfXtTFqMmkAB9KoNljuJJHpVplLE7hTfLHHp6UFbFcKSal2Y7VOsa7cqBUojzyaYij5QHrUE8S7fY1qSIO1VbiIDnNMErnOalZLPE6OgZWBGDXjnivRm0m9wgzbufkPp7V73JErr1rlfFOix6jaSRMOeqn0Na0qnKznr0OdabniHBbApDgsTn8K3rvwtqECuwj3qvUpzVCXRb+KPe9rKEz12mu08l6Oxn7smmuMgdqna1nGcxuPwNNaCZjxE+R7UARgc0VMLS4c/LE5P0ophc9Q8FrbwabLcXUKPtZiCwz0NcJ4s1VtU1WWU/d+6B7CprjxBNHposYjhMct3Nc8Tk5PU1DelgjGzbG1teHdON1OsjrlFPHuazLK3a5uo4l6scfSvTvDumqgRVX5V4zjrWU5WR0UafM7nW+F9PWKBMjnrXXRxAYwOtUNLhVIwMDpWqv3Rz9K5bnoJWRMoAUYqULkGmIMoPWnu2FHFMCByMnmq0xqaY8iqzkFsA1JaIJASCM4p1uR0NKw3tgCliUo59KoLFscKTTHTI3U9TkAdqWQgZGeKYiscMMY5pVj+cHpS7ccg0oYAjNJsaRIE5znrU6ofXgVEGBbORVmE+9ICaJQOc1MqnH8qjjZcHJwKcZOAFPFIZP0Xk9qqyPhtqinyNlRzVcnkE0gBkDL+8OeelIUJB28KKcSD9KCwCgD71Kw7ibcLk0w5cDPTtQ0h5ye1MXIXJIA+tMQxhjIzURyD7VNL0FQAEtnvSKVgKE8+lM8slhz1qwMgc9KcgOQe9AXIkh9+lWRF8oFIuASe9PST8aZNxrRgjHGBWbfx4P3sCtKVjk5HWqN0hJPy8CkzSnuZzblXgZFVZ42cnIxWmCNuDg1WnG4nAqbm3KmctqkE8auYG2se3ZvauQuvGlzbz3MWoWZ3Z2qm7gCvSruHK4NcfrWi2d1cq96pCqOXUcmuvD12nys8vHYOLXtEtTJi8X6W9w/m22LeOP92u0Es3vTG8XaUskAWwAjVCSdoyx9KsnwhpktwrbjGpTeyg8gUg8HabIIn811R88E849a9Bcx4n7sor4vsf3AFlsUlmkIAz7AUVcm8IafLbrJEzqAxUAn7w9c0UveC9M8zk5PNIOlKRmkAwcHrXOdh0XhG133Bkxz0Fep6DbldoI4FcT4HgU7Aem3Nel6SgGOK5qjuzvoxtFG7Zphc1aDktjsKpiUKnA4oSfLfKRnpWR0ctzTic4OKXzOuecVBGwEZajzBTuTYWVtwHHNVzmld+D2po569qCkhyggg1KY93zc1GjZbHpVyIgLg0IorplTzTypZac/XmnZAX3piZXxjHtTWY7hx+lSlsH2JqFnw2eCKVxpEq56t61YWQqMqMVT3fJx1zU8UhYnJ4xSuVysuRy4XmnPMoUYGaplsKNueO9RlicDmk2NQLbSgnB+tAcE5Kmq6Aq2SMjFPwTnnjFIGiTzlwdopUZSvvUMadRRg5piFJG7J5FKzrgg9qhYnJx0oiU5P0pDsx28HPpT4ym7JGaYEI5NWYY92SBxQSxjsrbVGMGp2RcDHWnRRfvRx0onO2XaOcc8UEXd7EGFyeKUFBwKbuO8bhxmjawYDtTY1ceSCRxxTGRGJHWpDtBPB5pMfe7c0DV7mfcQKrZxVaRFzmtWTG4EjcKqTwkLu2461DRvGT2ZmSxrg8DNZOoWySRscc1uvGXbJHeqV1DuyOhpFvXQ4C8gkhlk8tyHfCj2FVZPMDytk7o1CKT6mupvoRDcpK6BgrZoezjnntxInU+awC/eA6fSvSoJ1I3ufMY6l7GrotGc7bu4eOOZyRGueD1Jorof7PWWMEKAXckk9x2orb2UjgbR4YwwoNMX5mGfWpJT8qj0FPs4Gkbfj5AetZHprU9D8IxiNU7cV6JpwXauea4Tw4o+zxHjGK7fTxmMMGrkm9T0qa0L14+2NQveqzTGKPdjBJAH1q1ND5kaEckday9abyYrfn/AJajisep2RsonQGUJAoJ5PanKd1YkFy80nJHHFa1u3qe1WYk5GRg0+NdoxTUOc59anTFFxoFTJFWkAqqDhxUyvzjpSuVYlkj+XNQsBgAjmrIbMfNQleeTTuSQTABB61GqbsCpp0yfaomO3GDSbNIajioAAojAB5pqHIFSEYHB61JqkOJBXg0RYPXtTU7jNO4UHbQJjySoPTFM381Hv3UoG3k0IlslQnJNNZvmo3goR3qMMPWgS1HgVNCh696rRud/NWY3PagB7R5A5yaniT5QAcVED74NWEOV96CWPjUqTnpVDzQZ5Nx5zV8Njnsaxbh1Se4bOD1FJiir3LDMW6HnNSkgAMxxxWfaSAsCzVPJIGO1cY70y+XUsRyE4Ap2WZzuyAKigXBDE4zVlSM0dBNK4hjL52jApsqfK26pwwUcce5pkhBUikwTMyRGGGB4qjLGdx78VryoNhHUVTKAqxFSa30Oa1VN0Rx6Y+lc4L64hMw+YsyiNfQDPWuxv4gEbHBNcpJA0l55QOC33frXVhptSsjzMzpc9PmXQn/ALTfaEJVmAAzngUVBJp0xARkweuB6UV389Q+c0PFVVpJAo5J4rrLbT/Ks1XHvWLoUHm3BcjO2u6SHzIRtx0rmnKx7lGF1cdobGEAHoBXW2ExAVQcA1ytqoVcHgjpW7p02CCawmd9FLY7PThuU55A61zPjGfGp2sIxtRS/wDhXS6bdLFGO5NcN4muBP4nnwflXC/pUQWpc+praQW256mugjB2gisbRUPlg1vQjAoYktB+SAAOpqUenSmgd6DKc4x9TSGkTIvvUyJux7VUSY56DFW7Z8ucnFIbViyMgYPAqGRcNwaczN6jApjSZJJ6HpTFuRSeh71EyZ74xT3k+YHApZGJAwKTNIqxEqMM1KsJxmmKeTg9KnEny4oKbIgjAnnAqCWYr8oPJqa6mWKMs7AADk1lQStKxf8AKkK5owNgc4qdsACq9v05qZhuPTAHei4rXYgcg9eDSfx8dDSiJmPA49alKAA44NK5rZLYaGA/GrELgjA6VWWMOCBmpolKuB2xQJotxgFgKsqQqmq6qAcjqKRmOG9R2oMmrllJFKHmuX8TSmErJGM5IVvoTW8oJ6dKzNYtvPgdTjJFN2FC6kU7V8oCODVmJhvG498GqOngvAM8Hpn0q7EuxwX6A0Gty+HCnA5X3qaORWAPGKoghuQeKtRp8oIHFMxdyxvTfhcEVHPKP4cY/nQIyVbt9KgK/e4O2kyo6iNJvDYGD0qFipU1IUBHBwKgaM8gc1BbKF8qsTuHbiuX1WLY4ZDhgetddMhIwRkmsPUrXOcZIq4u2qIl7y5Wcbf+N4rG8ljmtXWRAFX39TRVPxL4eGp3KbCqSgYJJ6iivXp1JTjdHztbD06U3FnPaBamO2R+u7k11Wn4IZMj6GsXSbecRop44HyjtXR2mlbiHdiG68GuKbPWpRaQxYhlgv3hzVm0YBxzinvppT50uApH949aoTytBJuyjEd1bINZ7mqdmdfYXHygE9K5G+fzfE1z6bq1NPv0dRlgv1rl7i7jh8QTN5gZGbqKcI6sdSWh6Po5yv4YrZjYZAzXHabqMzYFtAxX+83ArSivL2TkoqDOMetQ9Ny4xctkdKWAXiqks3zZzWcj3kjctgewpXhuyGIIOPUVDaNo02tzSifcBVyAn1rCsZZCCkgKup5FXZr4W0WBzI/CCkDWhqPcZcRL174qcIGUDvWZpkbEZOSzHJJ71tLGQoI60yLFcQj0pTCMc1cWPpxSToQAwNA7lDZtHSn4yoH6U7aWPNUNduzY2DyR8Sv8kf1PejcTZjarcNd3xgiJEURwxHc1etoSFGKo6XbbY+ck9SfU1u20eAuabZSQRocZwevNXI4iRnB21MkaDHTntWNr2tixIt7fBmYZ+lSo3FzdjXG0Iu7A5qCdd7Zj6Vyqz3cpLyzue/tWpYXsm4Ryt9GNDRUTWgBLEAYqc8dR7VVtnxJyeau7gQCaLDluDqcg/rTguT168UFvl4IIxSK3PFKxFxrgx8A5zUExBU9zVrdkHcvSqcg5z60mFrmJbN5F1NFyDuyB7GrIf881V1b91NHKvrtY1H5xxnPAoRpa+pqCTBAXrir9s2QAeBWDaz7mz2rUjkA2gHk0xSXQ01ODgYxUUrY3YHy0iOHXHepVH7rDL9KTJVluZshOepFLjau45qy8Y7jIqNsHPZfSpsy3JFSRgRxzWZdjcSO5rXICfNj5TWdf4B4BqlsRpc5PVbXccHII70Vq30e9ckH8KK1jNpWRnOlCbvJHJWESrFvJwo70y91sxqUtcFh1cj9BVDUb3cvkxHbGOCR3qLTog0hcqD/CoxWyXVnM30RZtoJ71t91I5B7Zrp9K0JXxuUBfpTdIst7qNvArR1m9a2jFnanErD527qPT61m5X0RrGNkVtVbTbCJoyqyzDqiDOPqa5XStNS71YXDRjaDkL2FaLW+Uxgk9Sa0NLh8kHA5NNOy0Ha71OmsYI41QELj2q6baJckFTnkYrOhzgbjye1OaLaMgkMDkVlZG8W0y/G6KRjHWrsRiaNlBG7FcuZnjZir5PXBNQ2uuAjCgtN02e9JJmrSfUm1O5FlfIFG+STICjvjvVnS7Ge5uBcXWC54A7KKNLsy8huJ+ZXJ59PauggTGNvWrSMZzLVrblFXABq5tYNzgj0pLcNgcgYqVsjOcE0NGXMMG7uMUjgsvIpy7jySBTwDtosJyKaqQMY61yfiOZrnV47fjbCMke5rtLg+VG0nZRXn0TNPrV07/eLnmi1kEZXZt2ilQBtFasS8At6VltcR2sDSSuqKo5JNZkvigyrs02IynpvbhRSsaKV9jqZZQqcnGPWvNbrUBd+IbsxneqvgHtitRzf34IvLltrcFU4GKWx0W3tWPloEBOc+tCaSNFBslh85xljtHoKtKpIyHyRU4jjC9fapEii5IPPvUXuaOEUizZT7owD97oa0ElJTHesa1CpcqpbCvxk+taixlTjdzVIhsto2FIB56UpIUcnkVVLYzzzUXnFuCcYoIdy08mT14pkhB6nNUpmcDOePaot0kmMMPxqLlJE15Es8LI3RgRXNTXHk27xucSKdhz9a6ErIFwWUZ9647xhHLbXNlIGXZI+1+OtVFXYr2N+yPyLj0rWtky4OeKxNNfKLg8CtqEkYbpSKbNSFVQZPWpww9TVGJuhJ79+1S+aMnPQ0EWbJ2CsDnBHpVe4QAfJ3pscisxGCBUig9+e+Km5fJYqFCOG5HUVTul35J/GtdlGMnFUbgjacYyD0oBbmHLGGOwjiipZRmQk5op3G4nkRXcwXsBk1saZH8ygd6yID8zH1NbmkczjrxXXPY8+G52Gmj7OjSdlXj61lBWlmklflmJJNagc/YiOgHJqgjAQgCsEdT7ERQbh2zVqBNrADvVYn5+eKvW+DyDzQwjuadqoDc9qn3rKSO3TNVYWIU55q5HHi2TAwWOc1mdFktWV57FHToCPpVO10qGC6Z1/i7nrWyAQADSGHJziqTsTuX7WFVjUDpV2KPaOlZltO0XyOeOxNStqUKHDSrnOAM9apMxcXexso4HXikMyvnHUVjSX5zuOQPpTorok8DrRzXBwsbIKlQelTKVZRzWUs/GTk1aikJGSadzJi3YDnaf8AVjk+9edfa4rW7vJ5mCoHJ5713d7IVicjrivFPGNw4vDbgkDOSPeqiruxN7K5qSXdz4hvMtlLFD8q9mrp7GyWOMBQAPTFZ+h26x2cKgD5VAroY8DAFTNm9IekC4wF5FOEJckHgVYiATJzmj5nY9hWZupEMVluwSwxVn7GqggDPvSr8vFOMrBBtzQiJSbKV3agghc56iozqUcTLFOQkh7E9fpT7q5deFUsx7VnRWLSymac739+30p3Ek2aBvYnPEiZ9M0+NXcFlKt9DVA2wAxjimm22gFcqfY4pXK5DSPmY5U4FOXIH3W9elUI7q5hQ8+ap/vdakTVWAw0LZ9jQK1iwxZjyp/KuV8enZZW0hRgElH0q/qOs6gMCzgXnu5rDv7fU9YXZqFyfJznYgq4JLVmc7s1dFlV4lOetb6zADGenvXLWOmGFdgd8D1NaUdqRwSSPrS0K33NxJ+xYD2zVjzgUByPSsVLQA5wealEDBsoSMds1Fik0bcL87h0HarUWWwRx9a59LmaD7yhh+tadrerPxwGpAy9LGWwc4AqlcxYXK85q6WLqAG5zioJfvNuwSDjFUTExJ0bPfNFXJ8bjxiikjW66nhVtLyPcZroNKk/eg5rh7C8DIgY4ZePqK6rSpgQrCuycTyaU7nczSFdNcrjOzk1mwSbo0yetPScT6ZMsZG4Icis6wmDRRnrgYNY2OxSuzRdsYPXHFWrN8kCqfDAg9+lSWr7HFSzSL1Oms4vMHPatOaMpYo4Una3P0rJsbpAQueTXTWu2W3KZHPrUJXNZtow1lDEYPStG3G6P5hjnnNUb/TZoWMkXzITnb3oguC0BGSGGMimLdaGibdZ1KOOaof2HEs6yqi+apyDVmO8Yvk8kc5qY3fGWpaME5IGG/bGwxzmrK26gcYrPt7lXuskcVrR7WXINEUZzZWdGxjtSiVgOR0qwEG7NNdRtOMfSrsZ3RQmkyCCc14r4ikFz4kkCnI83aPoK9k1T93byOuRtUnPpxXiEZMuuKxOTvJrSl1ZE9j0TRmAhGeorejzj5sc/pWBpQ/dKMfN3rciG7PODismdEbJFiPHIBOasx5VSWIFVkBBzih2ZvlWkXuW0AcZzwatKq+WRxVRXVY1HepQ3UUEtXG+WjSHIFWY7RdvGOlQWZWRmHetKJMEKDimS9DMntQAQM1WMGBt61vTW5JGOlVjalW6fjSasUp3RlvbDaOOO9VJLbnA6VvSwAL3qs0PHyj86LBGRim2ULhqI7cD7uKvmLcSMHrQ0AXaw6Uti9yl5YBPFWYocgUyRTuODg1NE3ADcUJicNCRIsdKkFuCAc81Yji3LxnOOtSrGSuCMUGZnyQBgRgGqMtuUOUYgjpitpo9uSKglTKdKbBPUr2V6Yhsm4PrWsDFMvy45rFlt2Zc7ait55LdwOq56VN7Glr6o0bqLC496Kcbneoz3oo3BNrofJ6OUcEV0/h++BYozfSsRdOllWUoMlOoFQW7SxSgoDuWvSavofPwnyu6PTba4MOJF5Xow9QahRzZ3rQycI3KH1Brm9O1zgpMMZ65roBcwajYiJ3G5B+7cdR7Vi4WO2NVPY14Jg4HPtVq2fbKM9K5exvdkghnIDqcc963YJw0hyR7VnKNjrhNSOnhUMUYHBrYtpXVVAYYrm7C6ORG/XtW1bNuUj1rFqx2LVHQw3oaMB8HA9akTT7S6O4sqt3wcGublWeL5k+YU+C/dCC2R9ad+5g6bWx0B0q3j/iY+pzVKeGCIEDLN2yaji1EMME5Y9qoPM5vnD9ugpOwkn1ZfhiwAQMVehYhcZqlE26rKvjjGaa3JZbWUhsEUyTczZTimj5h6mpwdo6VW5F7FO6tzPBJG3VlK5rwu8ibTdf2SdUlwa9+kYGvIfifpph1H7VGMLLzn3FaU9HYzlqjZ0qXow59a6KBsjdXC+HrsSRRtnqBXY2spIyegHFRJWZtB3RoxEnO4mnkDGRVOOfDEMPpVhpAUAHX2rO5tZkhAK8U4ORnn2psZUx464pTtIx0zTt1C/Qt2YVFJQcmr1ux6nqaoWrAYGQKuRvzjFCIkaMbFyAO3r3qYRhQSSMmqkcvlkED8al8/f2FUZNMR1B6gEVVmUbenAq8ZV2HaBnpUBG7AYDmgFcz4lCjJGQfWo7hc4AGK0JFXaBjmqkvXGB9aho3g7u5nyQnBIA4pFUsRxWhtwhHc1CUUEetKxtzFq1IKYAPFTk9MdTUMLjAGAPpUwZG4PBFM52nciI4Of0qs5CqPU1ZcrwRnjrVWUbyOwoY0hdhKkdBistlCsQa1A4Vcc5rOu/9Z15qWaU07iH5QBnIopjN8oGM+1FBaPEpD/wjl429fMjuEH1XmnxWUTxPLbxtJOj+ZGqjO8HnBq94w0qe9vme2ViI1CnPAA7Yqr4an+wX9l5xOXYxuM8qa9OOup8nf3ebqQz6LFqkHmwhYbg5zGOq4rmbyC90+QxuXHvXqer6ZPY3B1HSEVTktNjnr3xU+nW+meIdNjUMZLojEgI5B7n8615L7CVWyv0PGjdTl9xlfcO+a6fRPEAbZFdEBx0f1+tO8T+Ep9OkzbxSPDz85HpXKOu1MFcN61lKHRnTTqte9FnsOm3qTBWBBNbSX/kcsDt9ewrwux1W8sZFa3nZcduors9F8fyKyxX1oki45ZOv5Vzyo9j06WOja0j1aDUg4BGCK0I7+JiokjQ49q4GDxDodyQw+0QSN/cXjJ9q2LYtIgaF3Knpu4rGUGjsjWhM7P7VbIjMqInHUDmsYfvGZ+5OaoRmQ8OxOK0Lc/KM1Nidti1auQR2FaUI3c1lDAkGM4rUs255+lNEzJgCCDUrMCOKMZHA4phHemZbkcpIxjpWJ4t0xdU0SZAo8xAXU/St91UgcdKgmXCFR0PWlezuUjxPw9IYJpIH4ZTkZrt7SclVIPsRWZ4v8PyWl3/aFghKn5nUDpUWlXiyKpU89x6VrL3ldBFOLsdSrjORViF+xxzWfZSfN83Q1cdQv3TWNjfm6GhGVVSFphcAYY81RN1sQ4HzDtSpOkyB0OT0IqraErVmnC+CMfnWjG4yM+mKxo3YIMirSTEAbsUkEkajOETnkdKl85RGpU9e9ZjzhgM0olyeD8tBPLdGk1wMZzye1M+0MQD3HpVLzsKOQajDEnvzQ2OMS411kkH1qCSQsQV6VVcnLbaPMIXBPapZpFW2LQkwMk8+9ML/ADDGKrF88E9KVZGPA5pXNUjRBAC89OgoZuueDVTzQCCetDSjGc8mkTystGcEEd6jDZHzjiqZlJcdvU1O0hMeO1MmSsEsgCgKOc96oXEmW9DUvmZY8cVTmyXyaTLhoAlC4JyTRUU529MUUA3c8+luJXnugzkj7Qg59MVzWvEp4ncJ8oDDGKKK9CG58nTWp6f4dkaXT4xIdwKnOea4fxJK9l4nhjtGMCFcER/L160UV1R+FGFL42j021VZtJt1lAcNHkhuc8V4f44t4rW7K26BF9BRRVVdh4bdnImV89f0q5pTs1zhjn5T2oornOzqdZpg+RT34r0nQ5GNpFk/w0UVz1T0sIaCMS3Jq/AflFFFc7O1luP7tXtOJKtk9KKKES9jTj+6aYACKKKpmRIija3HaoZANwFFFIFuVLlVMTAgEV5b4ojWx16P7IPK3n5gvQ0UVUNzSXws6G06L9KuuTs696KKQ2VpWODzVGKRk1BAhwGPIoooYkdNCxZRk5qZDzRRUrcsGY7hzSoTsJzzRRSK6Dxywz2FOycDmiimAjE560w/eooqXsOJDEcuc1ZiOCcUUVCNmMl+8DSgnFFFCCWwE8mnyE/rRRVIyluRMSGyKrSEl8nrRRQOJTkJK5PXJoooqWUf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In infants with atopic dermatitis, the face often turns red, forms tiny blisters, and forms scales and crusts. The trunk and arms can have similar symptoms, but those areas are usually less severely affected. That's because babies have an easier time scratching their face than other parts of their body, and scratching worsens the symptoms. This baby is squeezing the skin on his chest to relieve the intense itching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright &copy; McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24288=[""].join("\n");
var outline_f23_46_24288=null;
var title_f23_46_24289="Hip pain";
var content_f23_46_24289=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hip pain (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/46/24289/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24289/contributors\" id=\"au5319\">",
"       Bruce C Anderson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/46/24289/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24289/contributors\" id=\"se7143\">",
"       Karl B Fields, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?23/46/24289/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24289/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?23/46/24289?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIP PAIN OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The most common causes of hip pain are arthritis, bursitis, muscle strain, and nerve irritation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The hip is a \"ball and socket\" joint formed by the pelvic bones (the socket) and the end of the femur bone (the ball). Both bones are covered with a smooth layer of protective cartilage; loss of this cartilage from wear and tear, inflammation, or injury causes",
"     <strong>",
"      arthritis",
"     </strong>",
"     . (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=see_link\">",
"      \"Patient information: Arthritis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Bursitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The hip joint and the large muscles that cover it are lubricated by five large bursa sacs and the fluid contained in the hip joint. Each sac produces lubricating fluid and functions to reduce pressure and friction around the joint. These bursa sacs can become irritated from injury, excessive pressure, and overuse. Inflammation of a bursa is called",
"     <strong>",
"      bursitis",
"     </strong>",
"     . (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"      \"Patient information: Bursitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Muscle strain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Three major muscle groups help to move the hip through a wide range of movements. Overuse and irritation of these muscles can lead to",
"     <strong>",
"      muscle strain",
"     </strong>",
"     .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Nerve irritation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The major nerves controlling lower leg function cross the hip. Irritation of these nerves can cause pain through the hip",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     down the leg. Injury to the sciatic nerve frequently causes pain along the outer thigh or down the back of the leg; this is called",
"     <strong>",
"      sciatica",
"     </strong>",
"     . This is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"      \"Patient information: Low back pain in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      LIMIT ACTIVITIES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Hip arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have hip arthritis, you should avoid the extremes of hip motion and should minimize jarring and high impact activities:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Contact sports such as football, rugby, and wrestling, and stop-and-go sports such as basketball, tennis, and racquetball should be limited or avoided, at least temporarily. These activities can cause flares of arthritis and worsen arthritic damage.",
"      </li>",
"      <li>",
"       Avoid running and jumping",
"      </li>",
"      <li>",
"       Avoid activities that require you to spread your legs widely.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Hip bursitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Avoid repeated bending of the hip and direct pressure over the hip.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not sleep on the affected side; sleeping on the back or stomach is preferable.",
"      </li>",
"      <li>",
"       Stair climbing, stair stepper, step aerobics, rowing machine, bicycling, squatting, and stop-and-go sports (eg, tennis and racquetball) create too much friction and irritation and should be avoided until the pain has subsided.",
"      </li>",
"      <li>",
"       Avoid prolonged sitting.",
"      </li>",
"      <li>",
"       Minimize working in a stooped position.",
"      </li>",
"      <li>",
"       Limit repetitive bending at the hip.",
"      </li>",
"      <li>",
"       Do not bend over to touch the toes during the recovery period.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HIP PAIN RELIEF",
"     </span>",
"    </p>",
"    <p>",
"     If pain is bothersome, you can take a pain medication such as acetaminophen (Tylenol&reg;). A nonsteroidal antiinflammatory drug (NSAID), such as ibuprofen (eg, Advil&reg;, Motrin&reg;) or naproxen (eg, Aleve&reg;) can also be used for pain. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      STRETCHING FOR HIP PAIN",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Heat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heat helps prepare the tissues for stretching and is recommended before beginning each exercise session. The preferable method of heating is in a warm shower or bath for 10 to 15 minutes. Local heat (eg, with a heating pad or a towel warmed in a microwave) is an alternative, but may not be as effective.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Hip arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stretching exercises are recommended once per day, after heating the area.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Knee chest pulls",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lie on the back on a bed or on a towel on the floor. Bring knees up to chest. Place the hands behind the knees and pull toward the chest until you feel a stretch in the lower back and buttocks. Hold for a count of 5. Rest and repeat 15 to 20 times. (",
"     <a class=\"graphic graphic_picture graphicRef56440 \" href=\"UTD.htm?4/28/4545\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Figure of four stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stand next to stable piece of furniture (eg, couch). Stand on the unaffected leg and place the opposite foot along the inside of the knee (imagine a number 4). Gently rock the knee outward. The higher the foot is raised the greater the stretch. Hold for a count of five. Rest and repeat 15 to 20 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Sitting stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sit on the floor and place the feet together and the knees apart. Pull the feet up towards the groin. Lean forward gently to increase the stretch, but do not bounce. Hold for a count of five. Rest and repeat 15 to 20 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Hip bursitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cross leg pulls and outer thigh stretches are often recommended for people with hip bursitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Cross-leg pulls",
"     </span>",
"     &nbsp;&mdash;&nbsp;To perform cross leg pulls, cross the affected leg over the other while in a sitting position either in a chair or on the floor. Grasp the knee and pull the leg to the opposite side. Keep the buttocks flat; do not roll the pelvis. A gentle pulling sensation should be felt in the outer buttocks or hip area. Rest and repeat 15 to 20 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Outer thigh stretches",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stand at arms length away from a wall with the affected leg near the wall (",
"     <a class=\"graphic graphic_picture graphicRef74372 \" href=\"UTD.htm?26/40/27267\">",
"      picture 2",
"     </a>",
"     ). Cross the affected leg behind the other leg. Carrying all the weight on the good side, bend the elbow and lean into the wall. You should feel a stretch through the hip and side of the body. Rest and repeat 15 to 20 times.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      MUSCLE STRENGTHENING EXERCISES FOR HIP PAIN",
"     </span>",
"    </p>",
"    <p>",
"     Basic muscle strengthening exercises may be recommended if you require prolonged bedrest, have been in a cast, or have been inactive. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Straight leg raises",
"     </span>",
"     &nbsp;&mdash;&nbsp;These exercises are performed while sitting on the edge of a chair or while lying down (",
"     <a class=\"graphic graphic_picture graphicRef78695 \" href=\"UTD.htm?10/31/10736\">",
"      picture 3",
"     </a>",
"     ). Keep the affected leg straight and bend the knee of the other leg. Lift the affected leg three to four inches off the ground. Hold for 5 seconds. Rest. Repeat 15 to 20 times.",
"    </p>",
"    <p>",
"     With improved strength, these exercises can be performed with a five to 10 pound weight placed at the ankle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Leg extensions",
"     </span>",
"     &nbsp;&mdash;&nbsp;These exercises strengthen the muscles in the buttocks. Perform these exercises while lying on the stomach or while on all fours. Extend one leg backwards, hold straight, and raise it 3 to 4 inches off the ground. Hold for five seconds. Repeat 15 to 20 times for each leg.",
"    </p>",
"    <p>",
"     After three to four weeks, you can increase the difficulty of the exercise by adding a five to 10 pound weight to the ankle. Perform this exercise while lying flat if you have knee cap irritation or arthritis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      GOOD BODY MECHANICS TO PREVENT HIP PAIN",
"     </span>",
"    </p>",
"    <p>",
"     The following positions and activities are recommended to reduce the possibility of reinjury to the hip joint and the surrounding bursal sacs:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sit in a partially reclined position",
"      </li>",
"      <li>",
"       Sit up straight with your legs slightly turned out",
"      </li>",
"      <li>",
"       Stand with the weight equally distributed between your right and left legs",
"      </li>",
"      <li>",
"       Lift and carry weight close to the body",
"      </li>",
"      <li>",
"       Sleep on your back with the legs spread apart",
"      </li>",
"      <li>",
"       Sleep on the unaffected side of the body with a pillow between the knees",
"      </li>",
"      <li>",
"       Keep your weight under control",
"      </li>",
"      <li>",
"       Swim with the crawl kick (legs kept straight)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287481302\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530846290\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=see_link\">",
"      Patient information: Hip pain in older people (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=see_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/46/23266?source=see_link\">",
"      Patient information: Aseptic necrosis of the hip (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2530846327\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=see_link\">",
"      Patient information: Arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"      Patient information: Bursitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=see_link\">",
"      Patient guidelines for weight-resistance training in osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link\">",
"      Weight-resistance training in patients with osteoarthritis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"      file://orthoinfo.aaos.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"      www.niams.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Physical Therapy Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.apta.org/\">",
"      www.apta.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Arthritis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.arthritis.org/\">",
"      www.arthritis.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?23/46/24289?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f23_46_24289=[""].join("\n");
var outline_f23_46_24289=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIP PAIN OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           LIMIT ACTIVITIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HIP PAIN RELIEF",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           STRETCHING FOR HIP PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           MUSCLE STRENGTHENING EXERCISES FOR HIP PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           GOOD BODY MECHANICS TO PREVENT HIP PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/28/4545\" title=\"picture 1\">",
"           Single knee chest PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/40/27267\" title=\"picture 2\">",
"           Outer thigh stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/31/10736\" title=\"picture 3\">",
"           Straight leg raise PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f23_46_24290="Hydrocephalus due to a vein of Galen malformation";
var content_f23_46_24290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydrocephalus due to a vein of Galen malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vein of Galen malformation, causing hydrocephalus.",
"    <br>",
"     (Panels A-D) Axial T2 weighted magnetic resonance imaging (MRI).",
"     <br>",
"      (Panels E, F) Cerebral angiogram.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Drs. Abilash Haridas and Tadanori Tomita.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24290=[""].join("\n");
var outline_f23_46_24290=null;
var title_f23_46_24291="External hemorrhoid thrombosed";
var content_f23_46_24291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Thrombosed external hemorrhoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture depicts a classic thrombosed external hemorrhoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of W Brian Sweeney, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24291=[""].join("\n");
var outline_f23_46_24291=null;
var title_f23_46_24292="Angio subclavian steal syndrome";
var content_f23_46_24292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Arteriogram of the aortic vessels in subclavian steal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arteriography of the aortic arch vessels&nbsp;demonstrates a significant stenosis of the proximal&nbsp;innominate artery (panel A). Panel B shows reversal of flow in the right vertebral artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Spittell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24292=[""].join("\n");
var outline_f23_46_24292=null;
var title_f23_46_24293="Meperidine (pethidine): Patient drug information";
var content_f23_46_24293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Meperidine (pethidine): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     see \"Meperidine (pethidine): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/63/11255?source=see_link\">",
"     see \"Meperidine (pethidine): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Demerol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Demerol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3524863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower shivering.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702464",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to meperidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad lung disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion; very nervous; anger with sweating, shivering, stiffness, or shaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix syrup with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin or a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10838 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-41F16B85B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24293=[""].join("\n");
var outline_f23_46_24293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192763\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192764\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023374\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023376\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023375\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023380\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023381\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023383\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023378\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023379\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023384\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023385\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=related_link\">",
"      Meperidine (pethidine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/63/11255?source=related_link\">",
"      Meperidine (pethidine): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_46_24294="Epley maneuver";
var content_f23_46_24294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Particle repositioning maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with benign paroxysmal positional vertigo due to canalithiasis, the particle repositioning maneuver encourages the calcium carbonate debris to migrate toward the common crus of the anterior and posterior canals and exit into the utricular cavity. Step 1 is the standard Dix-Hallpike positioning test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reproduced with permission from: Foster CA, Baloh RW. Episodic vertigo. In: Rakel (Ed), Conn's Current Therapy, 47th ed, WB Saunders, Philadelphia, 1995. p.873.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24294=[""].join("\n");
var outline_f23_46_24294=null;
var title_f23_46_24295="Clinical manifestations and evaluation of thrombocytopenia in children";
var content_f23_46_24295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and evaluation of thrombocytopenia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Donald L Yee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24295/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/46/24295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia, defined as a platelet count of less than",
"    <span class=\"nowrap\">",
"     150,000/microL,",
"    </span>",
"    is clinically suspected when there is a history of easy bruising or bleeding in a child. It may also present as an incidental finding during routine evaluation or during laboratory investigations performed for other reasons.",
"   </p>",
"   <p>",
"    The clinical manifestations and evaluation of thrombocytopenia in children will be reviewed here. The causes of thrombocytopenia in children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link\">",
"     \"Causes of thrombocytopenia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, there are separate topic reviews that discuss thrombocytopenia during the newborn period, immune thrombocytopenia in children, as well as the approach to the child with a bleeding disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link\">",
"     \"Neonatal thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PLATELET COUNT AND BLEEDING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating platelets fulfill many critical hemostatic functions, including adhesion to sites of vascular injury, amplification of the platelet response, secretion of mediators of hemostasis, and aggregation via fibrinogen binding (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ). Bleeding risk, thus, increases with a low platelet count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link&amp;anchor=H2#H2\">",
"     \"Platelet biology\", section on 'Overview of platelet function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal platelet count for children ranges from 150,000 to",
"    <span class=\"nowrap\">",
"     450,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, the risk of bleeding does not increase until the platelet count falls significantly below",
"    <span class=\"nowrap\">",
"     100,000/microL.",
"    </span>",
"    For example, surgical bleeding solely due to a decreased platelet count typically does not occur until the platelet count is less than",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    Whereas, spontaneous bleeding does not occur until the platelet count is less than",
"    <span class=\"nowrap\">",
"     20,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The circulation time for platelets is about 8 to 10 days, after which they are removed from the circulation by cells of the monocyte-macrophage system. Younger circulating platelets are larger and more hemostatically active. For example, at a platelet count of",
"    <span class=\"nowrap\">",
"     20,000/microL,",
"    </span>",
"    patients with immune thrombocytopenia (ITP, previously known as idiopathic thrombocytopenic purpura), which is due to an immune-mediated destruction of platelets in the setting of a healthy bone marrow, have younger platelets and, consequently, less severe bleeding symptoms than patients with a similar degree of thrombocytopenia due to bone marrow failure from leukemia, whose platelets tend to be older and less active. Thus for a given platelet count, bleeding risk will be greater in patients with thrombocytopenia due to impaired platelet production as a result of an older circulating population of platelets. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Reticulated platelets'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When thrombocytopenia is recognized or suspected, implementing reasonable precautions to minimize bleeding risk is recommended. These include trauma precautions (eg, avoidance of contact sports and use of helmet while cycling) and avoidance of drugs that impair platelet function (eg, nonsteroidal antiinflammatory drugs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, children with thrombocytopenia may be asymptomatic, and thrombocytopenia may be first detected on a complete blood count obtained for another clinical issue. Symptomatic patients generally present with mucosal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cutaneous bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mucosal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal bleeding is usually manifested as epistaxis, gingival bleeding, and bullous hemorrhage, which appears on the buccal mucosa (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In postpubertal females, thrombocytopenia may present as menorrhagia (menstrual flow that does not taper after more than three days) and metrorrhagia (uterine bleeding between periods).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cutaneous bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous bleeding is usually manifested as petechiae or superficial ecchymoses (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 1",
"    </a>",
"    ). Patients with thrombocytopenia also may have persistent, profuse bleeding from superficial cuts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Petechiae are pinhead sized, red, flat, discrete lesions attributable to red cells, which have extravasated from capillaries. They often occur in crops in dependent areas, are nontender, and do not blanch under pressure. They are asymptomatic and not palpable, and should be distinguished from small telangiectasias and vasculitic (palpable) purpura (",
"      <a class=\"graphic graphic_picture graphicRef63367 graphicRef72094 \" href=\"UTD.htm?26/46/27367\">",
"       picture 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Purpura is a purplish discoloration of the skin due to the presence of confluent petechiae. Two types of purpura are generally recognized:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dry purpura refers to bleeding confined to the skin.",
"     </li>",
"     <li>",
"      Wet purpura denotes the presence of extensive mucous membrane bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not rigorously validated, the presence of wet purpura is widely perceived as the more serious of the two findings and a risk factor for potentially life-threatening hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ecchymoses are non-tender areas of bleeding into the skin. The affected area of the skin is usually associated with multiple colors due to the presence of extravasated blood (red, purple) and breakdown of heme pigment by skin macrophages (green, orange, yellow). Ecchymotic lesions characteristically are small, multiple, superficial, and can develop without noticeable trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of bleeding differs between patients with thrombocytopenia and those with disorders of coagulation factors, such as hemophilia. Patients with thrombocytopenia tend to have less deep bleeding into tissues, muscles and joints, more bleeding after minor cuts, less delayed bleeding, and less postsurgical bleeding. In addition, patients with coagulation disorders tend not to have petechiae. In patients with thrombocytopenia, posttraumatic or postoperative surgical bleeding usually responds to local measures but may persist for hours or days after small injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, bleeding into the central nervous system (CNS) is the most common cause of death due to thrombocytopenia. When CNS bleeding occurs, it is often preceded by a history of head trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in the evaluation of suspected thrombocytopenia in children is verification of a low platelet count. In particular, a platelet count that does not make sense within the context of the clinical picture should be confirmed before extensive evaluation is undertaken.",
"   </p>",
"   <p>",
"    Once thrombocytopenia has been confirmed, the evaluation is focused on determining the underlying etiology, so that directed therapeutic measures can be administered. The evaluation includes a detailed history, complete physical examination, and laboratory testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Verification of thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new finding of a low platelet count, especially if it is unexpected, should be validated early in the evaluation to ensure that thrombocytopenia exists and the finding is not due to artifact or laboratory error.",
"   </p>",
"   <p>",
"    Spurious thrombocytopenia can be caused by improper collection or inadequate anticoagulation of the blood sample resulting in platelet clumps that are counted as leukocytes by automated cell counters.",
"   </p>",
"   <p>",
"    In addition, agglutination of platelets by ethylenediaminetetraacetic acid (EDTA)-dependent antibodies, which are normally present in 0.1 percent of adults, may cause a falsely low platelet count (also referred to as pseudothrombocytopenia). EDTA exposes a normally concealed epitope on the platelet membrane, glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    which interacts with these antibodies resulting in platelet clumping. Examination of the blood smear will demonstrate large clumps of agglutinated platelets or adherent platelets surrounding neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be questioned about past and current bleeding symptoms including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bruising with little or no trauma",
"     </li>",
"     <li>",
"      Epistaxis",
"     </li>",
"     <li>",
"      Blood in the urine or stool",
"     </li>",
"     <li>",
"      Gum bleeding",
"     </li>",
"     <li>",
"      Bleeding with surgical or dental procedures",
"     </li>",
"     <li>",
"      The presence of menorrhagia and metrorrhagia in postpubertal girls",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following components of the history may provide clues to the underlying etiology of thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link\">",
"     \"Causes of thrombocytopenia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duration and onset of bleeding symptoms may help determine whether or not the cause of thrombocytopenia is acquired or congenital. If thrombocytopenia is due to an acquired etiology, the onset of symptoms may be linked to a specific trigger (eg, start of a new medication).",
"     </li>",
"     <li>",
"      Systemic symptoms (fever, bone pain, weight loss, and decreased energy) may suggest a systemic disease, such as malignancy or autoimmune disorder (eg, systemic erythematosus lupus [SLE]). In these patients, an expeditious evaluation should be performed because of the serious potential morbidity and mortality.",
"     </li>",
"     <li>",
"      History of other disorders that are associated with thrombocytopenia including cancer, sepsis, congenital heart disease, autoimmune disorders (eg, SLE), and hypersplenism.",
"     </li>",
"     <li>",
"      History of recent infections or vaccinations, which may have triggered thrombocytopenia. Measles-mumps-rubella (MMR) immunization is associated with a small increased risk of immune thrombocytopenia (ITP). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\", section on 'History'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dietary history, as thrombocytopenia may be associated with iron, vitamin B12, and folate deficiency.",
"     </li>",
"     <li>",
"      Review of medications, as many drugs may lower the platelet count including chemotherapeutic agents,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      , and certain antiepileptic drugs and antibiotics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"       \"Drug-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history of thrombocytopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucosal bleeding are suggestive of a genetic etiology, which include Wiskott-Aldrich syndrome or disorders related to mutations of the nonmuscle myosin heavy chain gene, MYH9. These MYH9-related disorders were previously separated into the clinical disorders: May-Hegglin anomaly, Fechtner syndrome, Epstein syndrome, or Sebastian syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H17#H17\">",
"       \"Causes of thrombocytopenia in children\", section on 'Genetic causes of impaired thrombopoiesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history of high-frequency sensorineural hearing loss, glomerulonephritis, or presenile cataract suggests the possibility of MHY9-related disease.",
"     </li>",
"     <li>",
"      Travel history &mdash; For example, malaria should be considered in a child with fever, splenomegaly, and recent travel history to endemic areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key components of the physical exam that may provide clues to the underlying cause of thrombocytopenia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gingival and oral cavity should be examined carefully for evidence of bleeding.",
"     </li>",
"     <li>",
"      Growth parameters &mdash; Short stature is a common finding in inherited bone marrow failure syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"       \"Inherited aplastic anemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sensorineural deafness &mdash; Megathrombocytopenia (thrombocytopenia with large or giant platelets) and sensorineural deafness have been described in families with mutations in the gene encoding nonmuscle myosin heavy chain 9 (MYH9) located on chromosome 22. These autosomal dominant, MYH9-related diseases also feature varying degrees and combinations of nephritis, cataracts, and leukocyte inclusions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\", section on 'Genetics'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes of thrombocytopenia in children\", section on 'Giant platelet disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ocular abnormalities may also be seen in patients with dyskeratosis congenita and Fechtner syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral leukoplakia (white patches or plaques of the oral mucosa due to squamous epithelium hyperplasia) is one of the three clinical manifestations characteristic of dyskeratosis congenita. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H13#H13\">",
"       \"Inherited aplastic anemia in children\", section on 'Dyskeratosis congenita'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphadenopathy may be indicative of an underlying lymphoid malignancy with bone marrow infiltration resulting in thrombocytopenia or some other proliferative process (eg, autoimmune lymphoproliferative disease or hemophagocytic lymphohistiocytosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Uncommon but important causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Splenomegaly, with or without hepatomegaly, from any cause can result in thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=see_link\">",
"       \"Approach to the child with an enlarged spleen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skeletal abnormalities may be indicative of specific syndromes associated with thrombocytopenia. For example, absent radii may be seen in patients with thrombocytopenia absent radius (TAR) syndrome and thumb abnormalities in patients with Fanconi anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"       \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H28#H28\">",
"       \"Neonatal thrombocytopenia\", section on 'Thrombocytopenia-absent radius syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Joint swelling may be seen in patients with autoimmune disease (eg, SLE). In some cases of SLE, chronic ITP may be the initial manifestation of this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27303?source=see_link&amp;anchor=H9#H9\">",
"       \"Hematologic problems in children and adolescents with systemic lupus erythematosus\", section on 'Thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin &mdash; Bleeding into the skin is one of the most common findings in patients with thrombocytopenia. Sites of bleeding should be noted, especially dependent parts of the body, and a marking pen may be used to outline areas of bleeding or demarcate involved and uninvolved skin area. Serial examinations can monitor the patient's clinical course by noting changes in the number of petechiae or bleeding pattern within involved areas. In hospitalized patients, careful examination for bleeding should be performed at the sites of indwelling catheters, drains and incisions, areas of previous trauma, and exit sites of venous access devices.",
"     </li>",
"     <li>",
"      Other cutaneous findings may be associated with specific underlying causes of thrombocytopenia and include eczema (ie, Wiskott-Aldrich syndrome), pigmentary and nail dystrophic changes (ie, dyskeratosis congenita), and hemangiomas (eg, Kasabach-Merritt syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H13#H13\">",
"       \"Inherited aplastic anemia in children\", section on 'Dyskeratosis congenita'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H21#H21\">",
"       \"Neonatal thrombocytopenia\", section on 'Kasabach-Merritt syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of thrombocytopenia begins with a complete blood count, which includes the platelet count and mean platelet volume (MPV), and evaluation of the peripheral blood smear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the complete blood count (CBC), the platelet count and mean platelet volume (MPV) should be noted, as well as evidence of any other cytopenias (ie, anemia and leukopenia).",
"   </p>",
"   <p>",
"    In a patient with thrombocytopenia, a MPV that is significantly higher (30 to 80 fL) than normal (7 to 10 fL) suggests one of the macrothrombocytopenia syndromes (eg, Bernard-Soulier syndrome or MYH 9-related disorders). A mildly elevated MPV is consistent with a destructive etiology, whereas a low MPV (3 to 5 fL) is typically seen in patients with Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia related to WAS gene mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link\">",
"     \"Causes of thrombocytopenia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Peripheral blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood smear must be carefully examined to estimate the platelet number, determine the platelet morphology, and the presence or absence of platelet clumping, and assess whether there are associated white and red blood cell changes.",
"   </p>",
"   <p>",
"    The following findings are suggestive of a specific etiology for thrombocytopenia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large platelets suggest either an ongoing platelet destructive process leading to the production of younger and larger platelets or the presence of a congenital macrothrombocytopenia syndrome (especially in the presence of extremely large platelets). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes of thrombocytopenia in children\", section on 'Giant platelet disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Circulating blast cells suggest a leukemic process.",
"     </li>",
"     <li>",
"      Small platelets in the appropriate clinical setting (eg, male patient with eczema and immunodeficiency) suggest Wiskott-Aldrich syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fragmented erythrocytes (schistocytes) suggest a microangiopathic process, such as disseminated intravascular coagulation, hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link\">",
"       \"Disseminated intravascular coagulation in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Microangiopathic hemolytic anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Microangiopathic hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spherocytes may suggest autoimmune hemolytic anemia coupled with autoimmune-mediated thrombocytopenia (Evans syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In these patients, the Coombs test will be positive. Less commonly, autoimmune-mediated neutropenia may also occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H28#H28\">",
"       \"Autoimmune hemolytic anemia in children\", section on 'Evans syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of isolated unexplained thrombocytopenia in children, a bone marrow examination is not urgently required unless bone marrow infiltration or failure is suspected. In such cases, the expected findings include either marrow infiltration with abnormal cells or marrow hypocellularity (with decreased megakaryocytes).",
"   </p>",
"   <p>",
"    In general, a bone marrow examination is indicated in patients with the following findings, which are suggestive of either marrow infiltration with abnormal cells or marrow hypocellularity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of involvement of other blood cell lines (ie, anemia and leukopenia)",
"     </li>",
"     <li>",
"      Presence of blasts on peripheral blood smear",
"     </li>",
"     <li>",
"      Presence of systemic symptoms (eg, fever, weight loss, bone pain) that are consistent with an underlying malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone marrow assessment also is indicated for chronic, stable thrombocytopenia even when the presumed diagnosis is ITP. ITP is a diagnosis of exclusion, and at our center, patients carrying this presumed diagnosis undergo a marrow exam no later than about six months after presentation of persistent thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following tests may be useful in determining the cause of thrombocytopenia. They are generally performed based upon suggestive findings from the initial laboratory evaluation (eg, complete blood count and peripheral blood smear), history, and physical examination. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complete blood count'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Peripheral blood smear'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A direct Coombs test is obtained to detect evidence of an autoimmune hemolytic anemia in a patient with evidence of hemolytic anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spherocytes on the peripheral blood smear.",
"     </li>",
"     <li>",
"      D-dimer and fibrinogen levels are useful to diagnosis intravascular coagulation in a patient with schistocytes on the peripheral blood smear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemangiomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link\">",
"       \"Disseminated intravascular coagulation in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Schistocytes on the peripheral smear may suggest other microangiopathies, in which case other additional tests should be considered including serum lactic dehydrogenase, creatinine, and ADAMTS13 activity. Elevation in serum creatinine may accompany macrothrombocytopenia in patients with Epstein and Fechtner syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Evaluation and diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link&amp;anchor=H21#H21\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Diagnostic criteria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link\">",
"       \"Causes of thrombocytopenia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening tests for inherited bone marrow failure syndrome should be considered in patients with chronic thrombocytopenia or when suspicion for such disorders (ie, pancytopenia with short stature) is high. For example, the presence of increased chromosomal breakage in lymphocyte cultures with DNA cross-linking agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C is diagnostic of Fanconi anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"       \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with giant platelets, and particularly those with a family history of thrombocytopenia, may have a disorder caused by a mutation of the myosin heavy chain gene (MYH9). MYH9 encodes the heavy chain A of non-muscle myosin of class II (NMMHC-IIA). The diagnosis of a MYH9-related disorder is confirmed by immunofluorescent identification of NMMHC-IIA protein aggregates in neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients suspected of having an MYH9-related disease can also have molecular genetic testing to identify a mutation. There are important genotype-phenotype correlations that inform management and prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/10\">",
"       10",
"      </a>",
"      ]. A list of clinical laboratories that perform this test is available at the",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/248472?db=genetests\">",
"       GeneTests",
"      </a>",
"      website. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes of thrombocytopenia in children\", section on 'Giant platelet disorders'",
"      </a>",
"      .) &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Reticulated platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not yet widely available in clinical laboratories, many reports indicate that quantification of reticulated platelets (RP) may provide useful information for differentiating between disorders of platelet destruction and production [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24295/abstract/11\">",
"     11",
"    </a>",
"    ]. Analogous to red blood cell reticulocytes, RP consist of the larger, younger, more recently released platelets containing mRNA and reflect increased platelet turnover. RP measurement methods have not been standardized, but usually have involved flow cytometric techniques utilizing fluorescent dyes such as thiazole orange to stain mRNA. Successful validation and standardization of reliable, automated methods for measuring RP are anticipated as a future aid in the to the evaluation of thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombocytopenia, defined as a platelet count of less than",
"      <span class=\"nowrap\">",
"       150,000/microL,",
"      </span>",
"      is clinically suspected when there is a history of easy bruising or bleeding in a child. It may also present as an incidental finding during routine evaluation or during laboratory investigations performed for other reasons.",
"     </li>",
"     <li>",
"      Spontaneous bleeding does not usually occur until the platelet count is less than",
"      <span class=\"nowrap\">",
"       20,000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Platelet count and bleeding risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic patients generally present with mucosal (epistaxis, gingival bleeding, bullous hemorrhage, and in postpubertal females, menorrhagia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metrorrhagia)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cutaneous (petechiae, purpura,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ecchymoses) bleeding. Although rare, bleeding into the central nervous system (CNS) is the most common cause of death due to thrombocytopenia. When CNS bleeding occurs, it is often preceded by a history of head trauma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in the evaluation of suspected thrombocytopenia in children is verification of the low platelet count. In particular, a platelet count that does not make sense within the context of the clinical picture should be confirmed before extensive evaluation is undertaken. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Verification of thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once thrombocytopenia has been confirmed, the evaluation is focused on determining the underlying etiology, so that directed therapeutic measures can be administered. The evaluation includes a detailed history, complete physical examination, and laboratory testing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombocytopenia with systemic symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of lymphadenopathy or hepatosplenomegaly should raise suspicion for malignancy or other proliferative process; evaluation should proceed expeditiously. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation of thrombocytopenia begins with a complete blood count and evaluation of the peripheral blood smear. The smear must be carefully examined for estimation of platelet number and morphology, presence or absence of platelet clumping, and evaluation of associated white and red blood cell changes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone marrow examinations generally are not required urgently in most cases of unexplained thrombocytopenia in children, unless marrow infiltration or marrow failure is suspected. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bone marrow examination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lusher JM. Clinical and laboratory approach to the patient with bleeding. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan, DG, Orkin, SH, Ginsburg, D, and Look, AT (Eds), Saunders, Philadelphia, 2003. p. 1515.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/2\">",
"      Vesely S, Buchanan GR, Cohen A, et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol 2000; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/3\">",
"      Crosby WH. Editorial: Wet purpura, dry purpura. JAMA 1975; 232:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/4\">",
"      Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/5\">",
"      Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program 2007; :29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/6\">",
"      Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/7\">",
"      Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol 1997; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/8\">",
"      Miller BA, Schultz Beardsley D. Autoimmune pancytopenia of childhood associated with multisystem disease manifestations. J Pediatr 1983; 103:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/9\">",
"      Savoia A, De Rocco D, Panza E, et al. Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010; 103:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/10\">",
"      Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24295/abstract/11\">",
"      Monteagudo M, Amengual MJ, Mu&ntilde;oz L, et al. Reticulated platelets as a screening test to identify thrombocytopenia aetiology. QJM 2008; 101:549.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5939 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-D7694A6197-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24295=[""].join("\n");
var outline_f23_46_24295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PLATELET COUNT AND BLEEDING RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mucosal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cutaneous bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Verification of thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Reticulated platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5939|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/17/7446\" title=\"figure 1\">",
"      Platelet interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5939|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/8/10372\" title=\"picture 1\">",
"      Petechiae in immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/32/33282\" title=\"picture 2A\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42721\" title=\"picture 2B\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=related_link\">",
"      Approach to the child with an enlarged spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=related_link\">",
"      Causes of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27303?source=related_link\">",
"      Hematologic problems in children and adolescents with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_46_24296="Tibial and fibular shaft fractures in children";
var content_f23_46_24296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tibial and fibular shaft fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24296/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24296/contributors\">",
"     Jennifer Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24296/contributors\">",
"     Joanna Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24296/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24296/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24296/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/46/24296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial shaft fractures are the third most common long bone fracture in children and are accompanied by a fibular shaft fracture in 30 percent of patients. Physical examination should carefully assess for the presence of an open fracture or signs of acute compartment syndrome. Most fractures are nondisplaced and may be managed with immobilization and orthopedic follow-up.",
"   </p>",
"   <p>",
"    The evaluation and management of pediatric tibial and fibular shaft fractures will be reviewed here. The general approach to tibial fractures, care of proximal tibial fractures in children, and stress fractures of the tibia and fibula are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link\">",
"     \"Overview of tibial fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=see_link\">",
"     \"Proximal tibial fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=see_link\">",
"     \"Stress fractures of the tibia and fibula\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial shaft fractures are the third most common fractures in children, after fractures of the femur and forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/1\">",
"     1",
"    </a>",
"    ]. The mechanism varies depending on the age of the patient, with low energy falls and twisting injuries being more common in younger children and high energy motor vehicle accidents and sports-related injuries predominating in older children and adolescents (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72158 \" href=\"UTD.htm?0/59/945\">",
"     image 1",
"    </a>",
"    ). The high-energy transmitted to the soft tissues surrounding the bone is relevant because of the significant risk for compartment syndrome associated with tibial shaft fractures. Thus, special attention should be paid to neurovascular status in the first 24 hours following such injuries. Open fractures, most commonly caused by vehicular related injury, are also a major concern with tibial shaft fractures because the anterior tibia is very close to the skin surface.",
"   </p>",
"   <p>",
"    Most tibial shaft fractures are short oblique or transverse fractures of the middle or distal third of the shaft. Tibial shaft fractures are associated with fibula fractures in 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"     2",
"    </a>",
"    ]. The average age at injury is eight years, and it is more common in boys than girls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weightbearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"UTD.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"UTD.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). The proximal portion of the bone, the tibial plateau, forms the lower surface of the knee joint. The distal end of the bone forms the superior articular surface of the ankle joint at the tibiotalar articulation and the medial malleolus. The tibial shaft bridges the proximal and distal ends and its anterior surface lies just below the skin.",
"   </p>",
"   <p>",
"    In children, both the tibia and fibula consist of a long portion of bone (the diaphysis) with growth plates at either end (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 1",
"    </a>",
"    ). The distal physes, particularly of the fibula, are areas vulnerable to fracture when subjected to inversion and eversion stresses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=see_link&amp;anchor=H26#H26\">",
"     \"Ankle fractures in children\", section on 'Distal fibula fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric bones have a lower cortical mineral content than adult bones, allowing children's long bones a greater degree of plasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, torus fractures and bowing deformities are injuries unique to the pediatric bone. While these injuries occur most commonly in the forearm, they are also seen in the tibia and fibula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H5#H5\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Buckle (torus)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H6#H6\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Plastic deformation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A strong fibrous structure, the interosseous membrane, connects the tibia and fibula along the length of the two bones. Proximally, this structure, reinforced by strong anterior and posterior ligaments, forms a synovial joint, the proximal tibiofibular articulation. Distally, the interosseous membrane and three ligaments (the anterior, posterior, and transverse tibiofibular ligaments) stabilize the superior ankle joint.",
"   </p>",
"   <p>",
"    Another fibrous structure, the crural fascia, surrounds the bones and muscles of the lower leg. Fascial extensions and the interosseous membrane separate the muscles, nerves, and vessels of the lower leg into four distinct compartments (",
"    <a class=\"graphic graphic_figure graphicRef66579 \" href=\"UTD.htm?4/40/4740\">",
"     figure 2",
"    </a>",
"    ). Three of these (the anterior, posterior, and deep posterior compartments) all border the tibia and can be compromised by tibial injury.",
"   </p>",
"   <p>",
"    Nerves and vessels lie within the anterior, lateral, and the deep posterior compartments (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"UTD.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"UTD.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66579 \" href=\"UTD.htm?4/40/4740\">",
"     figure 2",
"    </a>",
"    ). Trauma that causes significant swelling in these compartments can result in neurovascular compromise. The key blood supply of the tibia arises from periosteal vessels and the nutrient artery. The nutrient artery originates from the posterior tibial artery and enters the posterolateral cortex at the middle third of the tibial shaft near the origin of the soleus muscle. Fractures in this region have the potential to compromise this blood supply.",
"   </p>",
"   <p>",
"    Other aspects of tibial anatomy are described in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link\">",
"     \"Overview of tibial fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation in deforming force and in patient susceptibility lead to different fracture patterns in the lower leg:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Spiral (toddler's) and oblique fractures",
"      </strong>",
"      &ndash; Most of these injuries occur in children under 11 years of age when the child's body rotates around a fixed foot. In older children, the force is often substantial (eg, skiing, contact sports) and may involve the tibia and fibula. However, in toddlers this injury often results from relatively minor trauma of which the caregiver may be unaware or may dismiss as trivial (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67469 \" href=\"UTD.htm?9/25/9631\">",
"       image 2",
"      </a>",
"      ). Typically, the tibia is the only affected bone.",
"      <br/>",
"      <br/>",
"      In differentiating unintentional from abusive trauma in toddlers with spiral fractures, the clinician should understand that 90 to 95 percent of unintentional toddler's fractures of the tibia have a reported mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. In these instances, the described force is typically mild, and the fracture is minimally displaced. For example, the toddler or ambulatory infant may stumble and catch the foot between the bars of a crib, or may slip on toys on the floor while running. Like all long-bone fractures, spiral fractures are suspicious (but not pathognomonic) for abuse when the patient is too young to walk or lacks a consistent history (ie, of having had a twisting or rotational injury). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H18#H18\">",
"       \"Orthopedic aspects of child abuse\", section on 'Location and type of fracture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Transverse fractures",
"      </strong>",
"      &ndash; These fractures result from a direct blow to the lower leg that is perpendicular to the bone shaft and indicates a high degree of force (eg, motor vehicle collision) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72158 \" href=\"UTD.htm?0/59/945\">",
"       image 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Transverse fractures of the femur, humerus, or tibia are the most common type of long-bone fracture associated with abuse, comprising 48 to 71 percent of abuse-related fractures in various studies. Thus, child abuse should be suspected when the reported mechanism does not correlate with the degree of injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H18#H18\">",
"       \"Orthopedic aspects of child abuse\", section on 'Location and type of fracture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bowing fractures",
"      </strong>",
"      &ndash; Plastic bowing fractures are caused by axial loading that creates microfractures along the cortex and abnormal curvature of the bone [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/8\">",
"       8",
"      </a>",
"      ]. These fractures are more common in the radius and ulna, but may also be seen in the fibula. The abnormality may be subtle, requiring comparison views to detect on plain radiographs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H6#H6\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Plastic deformation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Torus (buckle) fractures",
"      </strong>",
"      &ndash; Torus fractures (also known as buckle fractures) are caused by compressive forces that lead to buckling of the cortex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H5#H5\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Buckle (torus)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fibular fractures",
"      </strong>",
"      &ndash; Approximately 30 percent of tibial fractures have an associated fibular fracture. Isolated fibular fractures indicate a direct blow to the outer aspect of the lower leg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of children with suspected tibial fractures is described in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of tibial fractures in children\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular shaft fractures have pain, swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity at the site of injury. Most patients are unable or unwilling to walk with the exception of those children with an isolated fibular fracture.",
"   </p>",
"   <p>",
"    Additional findings of specific fractures are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oblique or transverse fractures",
"      </strong>",
"      &ndash; These fractures are more likely to be open and are also at higher risk for compartment syndrome because of the high-energy mechanisms involved. Thus, careful examination for a puncture wound or laceration overlying the fracture and assessment of distal neurovascular status should occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of tibial fractures in children\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of tibial fractures in children\", section on 'Acute compartment syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Toddler's fractures",
"      </strong>",
"      &ndash; Eliciting localized pain over the site of injury may be difficult, particularly in a child who is already crying. There is usually no swelling or deformity of the distal tibia to guide the clinician to the site of injury. For classic toddler's fractures, placing the hands at the knee and ankle and gently twisting in opposite directions should illicit pain, as may gently grinding the heel of the foot into the distal tibia. The full range of motion at the hips, knees, and ankles is preserved and should be documented.",
"     </li>",
"     <li>",
"      <strong>",
"       Bowing or torus (buckle) fractures",
"      </strong>",
"      &ndash; Often, there is no swelling or minimal swelling at the fracture site. Patients with a torus fracture typically have identifiable bony point tenderness. Plastic deformation is visible only with significant angulation of the fracture although comparison with the unaffected side may allow detection of subtle differences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior-posterior (AP) and lateral plain radiographic views of the lower leg, including the knee and ankle, constitute the initial imaging of choice in the child with a suspected tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular shaft fracture.",
"   </p>",
"   <p>",
"    Based on the radiographic findings, tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular shaft fractures are classified by diaphyseal location (proximal, middle, or distal third), configuration (transverse, oblique, spiral), angulation, amount of displacement, degree of comminution, and degree of shortening.",
"   </p>",
"   <p>",
"    Additional radiographic features by type of injury are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toddler's fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toddler's fractures are a specialized case of spiral fractures of the distal tibia. The toddler's fracture is a nondisplaced fracture of the distal tibial shaft in patients in the age group from 9 months to 3 years, when weightbearing is just beginning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/9\">",
"     9",
"    </a>",
"    ]. The definition of toddler's fractures can be expanded to include fractures of other lower extremity bones including fractures of the foot, but the tibia is the most commonly affected bone because it bears most of the weight of the lower leg [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AP and lateral radiographs of the affected leg may show a faint hairline fracture, but this can be easily missed or inapparent on initial films in almost a third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/7\">",
"     7",
"    </a>",
"    ]. The AP view is the best view for observing the nondisplaced spiral fracture coursing along the distal tibia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67469 \" href=\"UTD.htm?9/25/9631\">",
"     image 2",
"    </a>",
"    ). Oblique views of the tibia can aid diagnosis when the AP and lateral plain radiographs are not revealing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, a child is brought to medical attention in a delayed fashion because of mild clinical symptoms and an unclear history. Seven to ten days after injury, there may be healing and periosteal reaction on radiographs which may look concerning for osteomyelitis or a bone tumor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51722 \" href=\"UTD.htm?31/25/32144\">",
"     image 3",
"    </a>",
"    ). In this case, a computed tomography (CT) may be warranted to exclude a more concerning lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone scintigraphy is very sensitive for toddler's fractures, but it exposes the child to significant amounts of radiation, often requires sedation, and is costly. Bone scans should therefore be reserved for more complicated patients who are febrile, lack a clear history of trauma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have elevated inflammatory markers (eg, erythrocyte sedimentation rate, C-reactive protein, white blood cell count) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/10\">",
"     10",
"    </a>",
"    ]. For example, in a series of 50 patients who met these criteria, 14 patients had septic arthritis or osteomyelitis and seven patients had lower extremity fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although operator dependent, extremity ultrasound may detect a fracture hematoma despite negative radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bowing fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures should be apparent on AP and lateral radiographs. A bowing plastic deformity exists but no clear fracture line is identified. Bone scans may rarely be necessary to confirm the diagnosis in uncertain cases (",
"    <a class=\"graphic graphic_picture graphicRef64894 \" href=\"UTD.htm?20/57/21396\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Torus (buckle) fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A buckle fracture typically occurs at the distal metaphysis of the tibia or fibula, where the bone is most porous, usually in younger children (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60438 \" href=\"UTD.htm?22/60/23489\">",
"     image 4",
"    </a>",
"    ). This injury is caused by buckling of the cortex due to compression failure. Torus fractures may be subtle, especially on the AP view.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathologic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with neuromuscular diseases, osteogenesis imperfecta, or bone lesions are at risk for tibial or fibular fractures, even after trivial trauma, such as moving from a bed to a wheelchair. The only clinical manifestation of fracture in such cases may be erythema overlying the anterior tibia, which can be confused with cellulitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features of cerebral palsy\", section on 'Osteopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a suspected tibial fracture should undergo evaluation and management appropriate to the patient's mechanism of injury and physical findings. The clinician should evaluate unstable patients and those with a high risk trauma mechanism (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"UTD.htm?0/42/684\">",
"     table 1",
"    </a>",
"    ) according to the principles of advanced trauma life support (ATLS) (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with closed tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular shaft fractures and no sign of neurovascular compromise, initial management focuses on pain control, immobilization of the fracture, and reduction of swelling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of tibial fractures in children\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Open fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to pain management and immobilization, these patients should receive antibiotics and tetanus prophylaxis (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 2",
"    </a>",
"    ). The antibiotic regimen should target Gram positive and Gram negative pathogens (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    and an aminoglycoside) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Consultation with a specialist in infectious disease is appropriate for patients whose wounds are contaminated with unusual substances (eg, animal feces, flood water).",
"   </p>",
"   <p>",
"    Open fractures of the tibia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibula warrant prompt orthopedic consultation for operative debridement, reduction, and fixation. Complications can include wound infection, osteomyelitis, and flap failure. Overall, limb salvage rates approach 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compartment syndrome may rarely occur prior to or after definitive orthopedic care of a tibial shaft fracture. When compartment syndrome is suspected based on clinical findings, immediate management includes relieving all external pressure on the compartment. Any dressing, splint, cast, or other restrictive covering should be removed. The limb should NOT be elevated. Elevation can diminish arterial inflow and exacerbate ischemia.",
"   </p>",
"   <p>",
"    Suspected compartment syndrome should prompt emergent orthopedic consultation. Compartment syndrome remains a clinical diagnosis. Although compartment pressure measurements can corroborate the clinical suspicion of a compartment syndrome, the patient with clear physical exam signs of a potential compartment syndrome should undergo fasciotomy with decompression of all involved compartments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Measurement of compartment pressures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a tibial shaft fracture in a child, especially a nonambulatory infant, with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient is stabilized, the medical care team should ensure that any child under two years of age with suspected intentional trauma be thoroughly evaluated, including a funduscopic examination by an ophthalmologist to assess for retinal hemorrhages and a skeletal survey. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt orthopedic consultation should be obtained in patients with any of the following tibial or fibular shaft fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Open fractures",
"     </li>",
"     <li>",
"      Fractures complicated by acute compartment syndrome or neurovascular compromise",
"     </li>",
"     <li>",
"      Pathologic fractures, especially in patients with spasticity or bone disease (eg, osteogenesis imperfecta)",
"     </li>",
"     <li>",
"      Unstable fractures (eg, fracture of the tibia and ipsilateral fibula, fracture of the tibia and ipsilateral femur)",
"     </li>",
"     <li>",
"      Displaced tibial fractures (eg, tibial fractures with &gt;10 degrees anterior angulation, &gt;5 degrees of varus or valgus angulation, &gt;1 cm of shortening).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of tibial and fibular shaft fractures depends on the bone affected, the type of fracture, and the degree of displacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nondisplaced tibial shaft fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Casting is the mainstay of treatment for nondisplaced tibial shaft fractures in children. Treatment consists of a long leg cast with the knee bent to 30 degrees for four to six weeks with frequent cast checks, followed by a short leg walking brace for an additional four to six weeks. The patient is ready for normal activity once full radiographic healing is demonstrated, and the fracture site is no longer tender to palpation.",
"   </p>",
"   <p>",
"    Prompt orthopedic evaluation is warranted for initial casting of children with tibial fractures associated with ipsilateral fibular fractures. However, subsequent treatment is not altered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Displaced tibial shaft fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displaced tibial fractures require reduction and casting with sedation or general anesthesia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72158 \" href=\"UTD.htm?0/59/945\">",
"     image 1",
"    </a>",
"    ). A short leg cast is applied first with the ankle in gentle plantar flexion. After the short leg cast is set, the rest of the cast is applied to the groin with the knee flexed 30 to 60 degrees. Casts applied during the acute phase of injury should be bivalved to allow for swelling. Post-reduction films should be taken to evaluate the degree of alignment and should be taken weekly for the following three weeks to evaluate for maintenance of reduction.",
"   </p>",
"   <p>",
"    We suggest that patients who require closed reduction of a tibial shaft fracture be admitted to the hospital to monitor for signs of acute compartment syndrome. This recommendation especially applies to patients with significantly malaligned or displaced fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fibular shaft fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibula fractures in conjunction with tibial fractures may be unstable and warrant prompt orthopedic evaluation regardless of displacement as previously discussed. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Nondisplaced tibial shaft fractures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Isolated fibular fractures may be initially managed with a stirrup splint, analgesics, ice, and elevation. The child should see an orthopedist with pediatric expertise within one week. At that time, patients may receive a short leg walking cast. Alternatively, the stirrup splint may be used for the entire period of immobilization, typically three to four weeks.",
"   </p>",
"   <p>",
"    Although the fibula is not essential to ambulation, children whose fractures are very painful or who are wearing a stirrup splint should be made nonweightbearing with crutches, as capable.",
"   </p>",
"   <p>",
"    Fibular fractures that involve the ankle joint are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=see_link\">",
"     \"Ankle fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Spiral (toddler's) fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with definite toddler's fractures on plain radiographs may be immobilized in a long leg splint with referral to an orthopedist within five to seven days or may be immediately casted (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67469 \" href=\"UTD.htm?9/25/9631\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Typical orthopedic treatment consists of a long leg cast for three or four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toddlers with a clear-cut history of trauma and an inability to bear weight on the affected extremity, regardless of negative radiographs, also warrant immobilization with a long leg splint or cast when a spiral fracture is the most likely cause for the symptoms until definitive diagnosis can be made. Such fractures usually become visible as a result of new bone growth approximately seven days after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bowing or torus (buckle) fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowing or torus fractures are not displaced and therefore stable (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60438 \" href=\"UTD.htm?22/60/23489\">",
"     image 4",
"    </a>",
"    ). Both of these fracture types completely heal when immobilized in a short leg cast or splint for three to four weeks. Children are usually made nonambulatory for the first one to two weeks. After that, ambulation, as tolerated, is allowed. Patients are usually referred to an orthopedist for follow-up within one week of the initial injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISCHARGE AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nondisplaced tibial fractures should be provided with immobilization (splint or cast) as previously described, made nonambulatory, and instructed to keep the fracture site elevated above the level of the heart as much as possible for the first 48 hours after injury. These patients may be discharged home with orthopedic follow-up in one week. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Nondisplaced tibial shaft fractures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children who receive a cast and their caretakers should be given detailed cast care instructions. Children should also receive crutches, if capable. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that patients who require closed reduction of a tibial shaft fracture be admitted to the hospital to monitor for signs of acute compartment syndrome for 24 to 48 hours. This recommendation especially applies to patients with significantly malaligned fractures and those rare patients who need external fixation and pinning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular shaft fractures that undergo closed reduction should be evaluated by an orthopedic surgeon within a week. Subsequently, the patient is seen on a frequent basis for the first few weeks to monitor for any displacement or angulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular fractures are rare. Sequelae of acute compartment syndrome and open fracture are of greatest concern.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Compartment syndrome",
"      </strong>",
"      &ndash; Compartment syndrome in tibial shaft fractures is significantly less common in children than in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/15\">",
"       15",
"      </a>",
"      ]. Direct intracompartmental pressures greater than 30 mmHg can cause irreversible damage to muscle and nerves and can result in permanent disability or limb amputation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"       2",
"      </a>",
"      ]. Most children and adolescents with early diagnosis and decompression with fasciotomy will not have long-term sequelae [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H17#H17\">",
"       \"Acute compartment syndrome of the extremities\", section on 'Disease course and prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Poor healing",
"      </strong>",
"      &ndash; Open tibial shaft fractures in children have delayed union or nonunion in almost 25 percent of injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/16\">",
"       16",
"      </a>",
"      ]. Infection at the fracture site increases the risk [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"       2",
"      </a>",
"      ]. An unstable fracture site is suggested by progressive angulation of the fracture, limited callus formation, and radiographic lucency at the site of fixator pins [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"       2",
"      </a>",
"      ]. Up to 10 degrees of angular deformity of the tibia in the coronal or sagittal plane in children eight years and younger remodels predictably [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/17\">",
"       17",
"      </a>",
"      ]. Clinically significant limb malunion causing pain or joint problems may require corrective osteotomy. Rotational malunion does not remodel and may result in gait disturbance or abnormal limb appearance, which may require surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Delayed bone healing, malunion, or nonunion is rare with closed tibial shaft fractures.",
"     </li>",
"     <li>",
"      <strong>",
"       Growth disturbance",
"      </strong>",
"      &ndash; Accelerated longitudinal growth after a tibial shaft fracture and subsequent leg length discrepancy is less common than with femur fractures, but children less than 10 years of age and those with comminution are at greatest risk for overgrowth [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24296/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with tibial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibular shaft fractures have excellent long-term outcomes. Patients with open fractures or compartment syndrome are at greatest risk for poor healing and infectious complications. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial shaft fractures are common in children. Young children may develop nondisplaced fractures after low energy falls and twisting injuries. High energy motor vehicle accidents and sports-related injuries are the typical mechanisms of injury in older children and adolescents (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72158 \" href=\"UTD.htm?0/59/945\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Mechanism of injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with tibial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibular shaft fractures have pain, swelling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deformity at the site of injury. Most patients are unable or unwilling to walk with the exception of those children with an isolated fibular fracture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oblique or transverse tibial shaft fractures may be complicated by an open fracture or acute compartment syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with torus, bowing, or toddler's fractures (nondisplaced spiral fractures of the tibial shaft) may have minimal swelling. Although torus or bowing fractures typically have bony tenderness over the site of injury, toddler's fractures may be difficult to localize. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anterior-posterior (AP) and lateral plain radiographic views of the lower leg, including the knee and ankle, provide appropriate initial imaging in the child with a suspected tibial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibular shaft fracture. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children under two years of age in whom child abuse is suspected should undergo a skeletal survey to evaluate for other bony injuries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link&amp;anchor=H8#H8\">",
"       \"Orthopedic aspects of child abuse\", section on 'Skeletal survey'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with closed tibial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibular shaft fractures and no sign of neurovascular compromise or multiple trauma, initial management focuses on pain management, immobilization of the fracture, and reduction of swelling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of tibial fractures in children\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to pain management and immobilization, patients with open fractures should receive antibiotics and tetanus prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). The antibiotic regimen should target Gram positive and Gram negative pathogens (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      and an aminoglycoside). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Open fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Displaced tibial shaft fractures, unstable fractures, pathologic fractures, open fractures, and fractures complicated by acute compartment syndrome or neurovascular compromise warrant prompt orthopedic consultation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nondisplaced tibial fractures should be provided with immobilization (splint or cast), made nonambulatory, and instructed to keep the fracture site elevated above the level of the heart as much as possible for the first 48 hours after injury. These patients may be discharged home with orthopedic follow-up arranged within 7 to 10 days of the day of injury. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Definitive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Discharge and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive management of displaced tibial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibular shaft fractures depends on the bone affected, the type of fracture, and the degree of displacement. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Definitive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who require closed reduction or operative care of a tibial shaft fracture be admitted to the hospital to monitor for signs of acute compartment syndrome for 24 to 48 hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Discharge and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of a tibial shaft fracture in a child, especially a nonambulatory infant, with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"       \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Heinrich SD, Mooney JF. Fractures of the shaft of the tibia and fibula. In: Rockwood and Wilkins' Fracutres in Children, 4th, Rockwood CA, Wilkins KE, Beaty JH.  (Eds), Lippincott-Raven Publishers, Philadelphia 2006. p.1033.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/2\">",
"      Mashru RP, Herman MJ, Pizzutillo PD. Tibial shaft fractures in children and adolescents. J Am Acad Orthop Surg 2005; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/3\">",
"      Shannak AO. Tibial fractures in children: follow-up study. J Pediatr Orthop 1988; 8:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/4\">",
"      Mabrey JD, Fitch RD. Plastic deformation in pediatric fractures: mechanism and treatment. J Pediatr Orthop 1989; 9:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/5\">",
"      Halsey MF, Finzel KC, Carrion WV, et al. Toddler's fracture: presumptive diagnosis and treatment. J Pediatr Orthop 2001; 21:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/6\">",
"      Tenenbein M, Reed MH, Black GB. The toddler's fracture revisited. Am J Emerg Med 1990; 8:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/7\">",
"      Shravat BP, Harrop SN, Kane TP. Toddler's fracture. J Accid Emerg Med 1996; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/8\">",
"      John SD, Moorthy CS, Swischuk LE. Expanding the concept of the toddler's fracture. Radiographics 1997; 17:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/9\">",
"      DUNBAR JS, OWEN HF, NOGRADY MB, MCLEESE R. OBSCURE TIBIAL FRACTURE OF INFANTS--THE TODDLER'S FRACTURE. J Can Assoc Radiol 1964; 15:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/10\">",
"      Miller JH, Sanderson RA. Scintigraphy of toddler's fracture. J Nucl Med 1988; 29:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/11\">",
"      Aronson J, Garvin K, Seibert J, et al. Efficiency of the bone scan for occult limping toddlers. J Pediatr Orthop 1992; 12:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/12\">",
"      Lewis D, Logan P. Sonographic diagnosis of toddler's fracture in the emergency department. J Clin Ultrasound 2006; 34:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/13\">",
"      Zalavras CG, Patzakis MJ, Holtom PD, Sherman R. Management of open fractures. Infect Dis Clin North Am 2005; 19:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/14\">",
"      Rao P, Schaverien MV, Stewart KJ. Soft tissue management of children's open tibial fractures--a review of seventy children over twenty years. Ann R Coll Surg Engl 2010; 92:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/15\">",
"      Bae DS, Kadiyala RK, Waters PM. Acute compartment syndrome in children: contemporary diagnosis, treatment, and outcome. J Pediatr Orthop 2001; 21:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/16\">",
"      Hope PG, Cole WG. Open fractures of the tibia in children. J Bone Joint Surg Br 1992; 74:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24296/abstract/17\">",
"      King J, Diefendorf D, Apthorp J, et al. Analysis of 429 fractures in 189 battered children. J Pediatr Orthop 1988; 8:585.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6550 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24296=[""].join("\n");
var outline_f23_46_24296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toddler's fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bowing fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Torus (buckle) fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathologic fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Open fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nondisplaced tibial shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Displaced tibial shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fibular shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Spiral (toddler's) fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bowing or torus (buckle) fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISCHARGE AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6550|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/59/945\" title=\"diagnostic image 1\">",
"      Distal tibia fibula fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/25/9631\" title=\"diagnostic image 2\">",
"      Toddlers fracture tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/25/32144\" title=\"diagnostic image 3\">",
"      Healing toddlers fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/60/23489\" title=\"diagnostic image 4\">",
"      Buckle fracture tibia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6550|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 1\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/40/4740\" title=\"figure 2\">",
"      Cross section lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 3\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6550|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42213\" title=\"picture 1\">",
"      Anterior anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/45/27349\" title=\"picture 2\">",
"      Lateral anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/57/21396\" title=\"picture 3\">",
"      Bowing fracture fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/684\" title=\"table 1\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24345?source=related_link\">",
"      Ankle fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42838?source=related_link\">",
"      Overview of tibial fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=related_link\">",
"      Proximal tibial fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19527?source=related_link\">",
"      Stress fractures of the tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_46_24297="Treatment of polycystic ovary syndrome in adolescents";
var content_f23_46_24297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of polycystic ovary syndrome in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Robert L Rosenfield, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24297/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/46/24297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) should be considered in any adolescent girl with menstrual irregularity, hirsutism, or obesity. Acanthosis nigricans, persistent acne, scalp hair loss, or hyperhidrosis may alternatively be the chief complaint, although these features are not always present.",
"   </p>",
"   <p>",
"    PCOS, a hyperandrogenic disorder, is the most common cause of infertility in women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of PCOS has life-long implications with increased risk for infertility, metabolic syndrome, type 2 diabetes mellitus, and possibly cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for PCOS in adolescents is directed at the following clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Menstrual irregularity",
"     </li>",
"     <li>",
"      Cutaneous hyperandrogenism, primarily hirsutism and acne",
"     </li>",
"     <li>",
"      Obesity and insulin resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several treatment options have been developed for each of these in adults (there are few studies in adolescents), and some options address more than one symptom (",
"    <a class=\"graphic graphic_table graphicRef67829 \" href=\"UTD.htm?4/54/4974\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The choice of therapy depends on the individual adolescent's symptoms and her goals. The treatment of PCOS in adolescents is presented here. The definition, pathophysiology, clinical features, and diagnosis of PCOS are discussed separately. Management of PCOS in adolescents includes evaluation of primary relatives because the hyperandrogenism and metabolic components of the syndrome have familial elements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link&amp;anchor=H1960542#H1960542\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Evaluation of family members'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MENSTRUAL IRREGULARITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual irregularity should be treated in adolescents with polycystic ovary syndrome (PCOS) because chronic anovulation increases the risk of developing endometrial hyperplasia, which is associated with endometrial carcinoma. In addition, anemia can result from dysfunctional uterine bleeding or menorrhagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Dysfunctional uterine bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Combination OCPs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination oral contraceptive pill (OCP), which contains estrogen and progestin, usually is the first-line treatment for adolescents with PCOS and menstrual irregularity, especially in patients with cutaneous signs of androgen excess. OCPs induce regular menstrual periods with a higher degree of reliability than other forms of treatment. Progestin inhibits endometrial proliferation, preventing hyperplasia. Estrogen inhibits the activity of the hypothalamic-pituitary-gonadal axis, reducing ovarian androgen production as well as increasing serum sex hormone binding globulin (SHBG) levels. This results in decreased concentrations of unbound testosterone. OCP therapy also will normalize androgen levels within 18 to 21 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H23#H23\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Hormonal contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many choices of OCP, and we recommend using one that has a progestin with antiandrogenic or minimal androgenic activity. The particular agent that is recommended depends upon the clinical manifestation(s) of the individual patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drospirenone, an analogue of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      with weak antiandrogenic and antimineralocorticoid properties, is combined with ethinyl estradiol: 20 mcg for",
"      <span class=\"nowrap\">",
"       24/28",
"      </span>",
"      days (in Yaz&reg;) or 30 mcg for",
"      <span class=\"nowrap\">",
"       21/28",
"      </span>",
"      days (in Yasmin&reg;) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/5\">",
"       5",
"      </a>",
"      ]. Its unique properties seem particularly well-suited for patients with PCOS because it addresses hirsutism and weight-control issues as well as menstrual irregularity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/1\">",
"       1",
"      </a>",
"      ]. However, like other third-generation progestins, it seems to carry about a twofold increased risk of venous thromboembolism in first-time users [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Norgestimate is a potent progestin with low androgenic effect and is combined with ethinyl estradiol: 35 mcg (in Ortho-Tri-Cyclen&reg;). It is especially useful for patients with associated acne vulgaris, for which it has received US Food and Drug Administration (FDA) approval. There is variable absorption of this medication, and adjustment of dose may be necessary.",
"     </li>",
"     <li>",
"      Ethynodiol diacetate (1 mg), a progestin of low androgenic potential, is combined with ethinyl estradiol 35 or 50 mcg (in Zovia&reg;",
"      <span class=\"nowrap\">",
"       1/35-28",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       1/50-28,",
"      </span>",
"      respectively). The",
"      <span class=\"nowrap\">",
"       1/50",
"      </span>",
"      preparation is useful for patients who require a large dose of estrogen, such as those with obesity or dysfunctional uterine bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After three months, the efficacy of treatment is assessed by evaluating menstrual symptoms and androgen levels. If the treatment is effective, as a general rule, OCPs should be continued until the patient is gynecologically mature (five years postmenarcheal) or has lost a substantial amount of excess weight. At that point, withholding treatment for a few months to allow recovery of suppression of pituitary-gonadal function and to ascertain whether the menstrual abnormality is persistent is advisable. In doing so, however, one must keep in mind that the anovulatory cycles of PCOS lead to relative infertility, not absolute infertility. The need for continued use of the OCP for contraceptive purposes must be considered.",
"   </p>",
"   <p>",
"    If treatment is not successful in reducing androgen levels, the patient either has an unusually prominent component of functional adrenal hyperandrogenism to the PCOS, or the diagnosis of PCOS should be questioned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of OCPs in the management of PCOS in adolescents may be limited for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OCP therapy may make weight loss more difficult to attain because it promotes salt and water retention.",
"     </li>",
"     <li>",
"      The patient may believe the treatment is curative and defer a definitive diagnostic work-up.",
"     </li>",
"     <li>",
"      OCPs do not permit conception if and when it is desired.",
"     </li>",
"     <li>",
"      In perimenarcheal girls with short stature who have open epiphyses, OCPs are contraindicated because OCPs contain growth-inhibitory amounts of estrogen.",
"     </li>",
"     <li>",
"      Concerns have been raised that the incompletely mature adolescent neuroendocrine system may have heightened risk for post-pill amenorrhea and infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/8\">",
"       8",
"      </a>",
"      ]. However, this hypothetical concern is based on observations in other patient groups undergoing treatment with high-dose estrogens during adolescence, and its relevance to girls with PCOS is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risks of OCPs are similar in adolescents with PCOS to those without PCOS. There is a risk of venous thromboembolism with use of OCPs that is primarily related to the dose and duration of estrogen use, although third-generation progestins such as drospirenone confer about a twofold independent risk for first-time users [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A detailed discussion of the risks and side effects of combined OCPs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual irregularities in sexually mature adolescents often can be controlled with cyclic progestin alone. Transient reduction in androgen levels is variably achieved during cyclic therapy, but this is insufficient to expect improvement in hirsutism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Micronized progesterone (Prometrium&reg;, 100 to 200 mg given orally at bedtime) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (Provera&reg;, 10 mg given orally at bedtime) can be used for 7 to 10 days out of each month or cycle. Progesterone itself confers no risk for cardiovascular disease or breast cancer and may lessen the small estrogen-related increase in risk in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Progestin therapy in a six-week cycle can permit the detection of the emergence of normal menstrual cyclicity. As an example, the perimenarcheal girl who responds well to progestin therapy can be maintained on six-week cycles, permitting the detection of spontaneous menses.",
"   </p>",
"   <p>",
"    Side effects of progestin include mood symptoms (eg, depression), bloating, and breast soreness. Patients must be informed that oral progestin prescribed in this manner (ie, 7 to 10 days each month) is",
"    <strong>",
"     not",
"    </strong>",
"    a means of contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable controversy about the efficacy and safety of glucocorticoid therapy for PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/13\">",
"     13",
"    </a>",
"    ]. Glucocorticoid therapy does not result in consistent ovulation in patients with PCOS, even in those with a prominent component of functional adrenal hyperandrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If glucocorticoid therapy is attempted because of a prominent adrenal source of androgen, the side effects of glucocorticoid therapy usually can be minimized by using a modest bedtime dose (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose of 5 to 7.5 mg), which reduces adrenal androgen selectively without causing adrenal atrophy. A three-month trial of glucocorticoid therapy seems sufficient to determine efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/14\">",
"     14",
"    </a>",
"    ]. Significant suppression can be excluded if the cortisol level is &ge;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (276",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    at 8 AM or &ge;13",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (359",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    30 minutes after administering adrenocorticotropic hormone (ACTH [cosyntropin]) at a very low dose (1.0",
"    <span class=\"nowrap\">",
"     mcg/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/15\">",
"     15",
"    </a>",
"    ]. Such treatment should be undertaken and monitored by an endocrinologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link&amp;anchor=H12#H12\">",
"     \"Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents\", section on 'Functional adrenal hyperandrogenism (FAH)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin releasing hormone (GnRH) agonist therapy (eg, depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    ) is used rarely in lieu of OCPs to regulate menstrual cyclicity or suppress ovarian function in the unusual patient who cannot tolerate OCPs and for whom progestins do not suffice. GnRH therapy is generally not recommended in adolescents younger than 16 years of age because of concerns regarding bone mineral accrual.",
"   </p>",
"   <p>",
"    Patients who receive GnRH agonist therapy also should be treated with low-dose physiologic estradiol and cyclic progestin add-back therapy (eg, 100 mcg estradiol transdermal patch) to maintain vaginal lubrication and to ensure bone mineral accrual if used during adolescence. Bone mineral density should be monitored during therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=see_link&amp;anchor=H207353414#H207353414\">",
"     \"Gonadotropin releasing hormone agonists for long-term treatment of endometriosis\", section on 'GnRH with add-back therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the therapies discussed above, treatments that reduce insulin resistance also improve ovulation and hyperandrogenemia in PCOS. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Insulin resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dysfunctional uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunctional uterine bleeding (DUB) is a common manifestation of PCOS and often is the initial presenting complaint. Treatment of DUB is similar in adolescents with PCOS to those without PCOS. Therapy consists of either treatment with cyclic progestin alone or with combination OCP. In general, adolescent patients with active bleeding have a better response with the addition of estrogen provided by combination OCP compared with progestin therapy alone. Patients with PCOS are often obese",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have severe bleeding, and an OCP with a relatively large estrogenic component such as Zovia&reg;",
"    <span class=\"nowrap\">",
"     1/50",
"    </span>",
"    may be required to control menstrual irregularity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/16\">",
"     16",
"    </a>",
"    ], although this increases risk of thromboembolic events. The different hormonal therapy options, clinical regimens, and general care for girls with severe DUB are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gynecologic referral is indicated for patients whose bleeding cannot be controlled medically or who have uncontrollable menstrual abnormalities despite OCP therapy. Their anovulation places them at increased risk for developing endometrial carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once active bleeding is controlled, therapy with cyclic OCP or progestin should be started to prevent recurrence of DUB. As discussed above, the choice of treatment depends upon the clinical manifestation(s) of the individual patient and treatment should be continued until the patient is gynecologically mature (five years postmenarcheal) or has lost a substantial amount of excess weight. At that point, withholding treatment for a few months to allow recovery of the suppressed pituitary-gonadal axis and to ascertain whether the menstrual abnormality is persistent is advisable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CUTANEOUS HYPERANDROGENISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperandrogenism is clinically manifested in two-thirds of cases by hirsutism or equivalent cutaneous findings including acne vulgaris, pattern alopecia, seborrhea, hyperhidrosis, and hidradenitis suppurativa. Hirsutism can be treated by cosmetic and dermatologic measures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by medical endocrinologic therapy. Medical endocrinologic therapy also will treat the other clinical findings of hyperandrogenism including acne vulgaris; topical retinoids or antimicrobial agents may also be helpful for treating the acne. A summary on the treatment of hirsutism will be presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. More detailed discussions, including the 2008 Endocrine Society Guidelines on the treatment of hirsutism, are found separately [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link\">",
"     \"Treatment of acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24266?source=see_link\">",
"     \"Treatment of hidradenitis suppurativa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cosmetic and physical measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masking the presence of excess hair and physical hair removal are cornerstones to treat hirsutism; however, their costs are not covered by third-party payers. Nevertheless, cosmetic and physical measures are effective either alone or as a supplement to medical therapy. The decision among these options involves patient preference including cost of the measure, tolerance of",
"    <span class=\"nowrap\">",
"     discomfort/pain,",
"    </span>",
"    risk of complications, and outcome. Patients with known hyperandrogenemia should also receive pharmacologic therapy to prevent hair regrowth.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shaving, chemical depilatory agents, bleaching, and waxing techniques are effective but can cause skin irritation. These measures are relatively inexpensive compared with other options. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link&amp;anchor=H4#H4\">",
"       \"Removal of unwanted hair\", section on 'Temporary methods'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37652?source=see_link\">",
"       Eflornithine",
"      </a>",
"      hydrochloride cream (Vaniqa&reg;) is a topical agent that is US Food and Drug Administration (FDA) approved for the removal of unwanted facial hair in women. It inhibits hair growth and takes about six to eight weeks for clinical effect. It needs to be used indefinitely to prevent regrowth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link&amp;anchor=H10#H10\">",
"       \"Removal of unwanted hair\", section on 'Pharmacologic options'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laser therapy (and equivalent light source therapy) removes hair permanently by thermal destruction of the dermal papilla. FDA-approved devices will permanently reduce hair density by 30 percent or more with three to four treatments of a site. This treatment can only be applied to a limited area, but is a somewhat more efficient means of hair removal than electrolysis. In some individuals, especially heavily tanned or darker-skinned patients, burns with residual pigment changes and scarring may occur. The costliness of the therapy limits its use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link&amp;anchor=H11#H11\">",
"       \"Removal of unwanted hair\", section on 'Laser and intense pulsed light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolysis can remove hair permanently because it destroys the dermal papilla. It is a slow, expensive therapy that can be uncomfortable and occasionally causes scarring. Because of the expense and discomfort, electrolysis is generally only practical for treating limited areas of the body. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link&amp;anchor=H12#H12\">",
"       \"Removal of unwanted hair\", section on 'Electrolysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical endocrinologic treatment of hirsutism and hirsutism equivalents (eg, acne or pattern alopecia) are another treatment option. All hormonal treatment for hirsutism or pattern balding is off-label [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]; however, oral contraceptive pills (OCPs) are FDA-approved for the treatment of acne. &nbsp;",
"   </p>",
"   <p>",
"    The goal of endocrinologic therapy is to decrease the effect of excess androgens by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reducing their production",
"     </li>",
"     <li>",
"      Reducing serum free androgen levels by increasing androgen binding to plasma-binding proteins",
"     </li>",
"     <li>",
"      Blocking androgen action at the level of target organs (eg, hair follicle)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Combination OCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCPs are effective in typical polycystic ovary syndrome (PCOS) patients in whom functional ovarian hyperandrogenism is the predominant source of androgen excess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link&amp;anchor=H11#H11\">",
"     \"Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents\", section on 'Functional ovarian hyperandrogenism (FOH)'",
"    </a>",
"    .) The 2008 Endocrine Society Guidelines suggest oral contraceptives (OCP) as the first-line drug for pharmacologic therapy. For the majority of women with hirsutism who choose pharmacological therapy, we suggest oral contraceptives as initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OCPs lower serum free testosterone levels mainly by decreasing ovarian production via suppression of serum gonadotropin levels and increasing sex hormone binding globulin (SHBG) levels. They also modestly lower dehydroepiandrosterone (DHEA) sulfate levels. The use of OCPs prevents further transformation of vellus to terminal hairs that occurs with androgen exposure. In most patients with PCOS, treatment with OCPs can be expected to arrest progression of hirsutism, reduce the need for shaving by about half, and improve acne within three months. It is reasonable to check androgen levels after three months of therapy to determine that androgen levels are lowered, as expected in typical PCOS.",
"   </p>",
"   <p>",
"    The OCP preparation selected should have minimal androgenic activity, and the author recommends one of the three nonandrogenic OCPs previously discussed based upon the clinical symptoms of the patient. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Combination OCPs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the combination of",
"    <span class=\"nowrap\">",
"     norgestimate/ethinyl",
"    </span>",
"    estradiol has FDA approval for the treatment of acne vulgaris, any OCP is likely to be effective in treating hirsutism and acne. A comparison of controlled trials for the treatment of acne suggested drospirenone and norgestimate (ethynodiol diacetate was not included) were beneficial in the treatment of severe facial acne [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H929891898#H929891898\">",
"     \"Treatment of hirsutism\", section on 'Oral contraceptives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids do not seem to be of substantial benefit in treating the hirsutism and acne of PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Glucocorticoid therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antiandrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiandrogenic therapy, which inhibits binding of androgen to its receptor, is required if there is to be substantial improvement of hirsutism. The decision to add an antiandrogen to an OCP depends on considerations of efficacy, side effects, and costs.",
"   </p>",
"   <p>",
"    The 2008 Endocrine Society Clinical Guidelines on hirsutism suggest adding an antiandrogen in patients taking OCPs who feel that their cosmetic response is suboptimal after six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is considerable individual variation, antiandrogenic therapy reduces hirsutism by one-third, on average. Antiandrogens act by inhibiting the androgen-induced transformation of vellus to terminal hairs. Thus, the effects of these agents usually are not appreciated for 9 to 12 months because of the long growth cycles of sexual hair follicles.",
"   </p>",
"   <p>",
"    Antiandrogens should be prescribed with an OCP because they may cause menstrual disturbance and their potential teratogenic feminization of the male fetus. Antiandrogens have only a modest effect on the metabolic abnormalities associated with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/20\">",
"     20",
"    </a>",
"    ]. A nonandrogenic OCP seems advisable, as discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Combination OCPs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The antiandrogens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      probably is the safest and most potent antiandrogen available in the United States and is the recommended choice for antiandrogen therapy. It lowers hirsutism by approximately one-third, which is demonstrated by a decrease in the hirsutism score using the Ferriman-Gallwey system (",
"      <a class=\"graphic graphic_figure graphicRef66629 \" href=\"UTD.htm?35/12/36035\">",
"       figure 1",
"      </a>",
"      ), although there is considerable variation among individuals. The randomized control trials and meta-analysis demonstrating the benefit of spironolactone are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of hirsutism\", section on 'Antiandrogen therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We recommend starting with 100 mg twice a day until maximal effect has been achieved and then reducing the dose to 50 mg twice a day for maintenance therapy as tolerated. Spironolactone must be administered as long as the patient wishes to maintain her improvement in hirsutism. Administered in these doses, spironolactone usually is well tolerated, but fatigue and hyperkalemia may limit its usefulness. Laboratory testing of electrolytes and liver function tests should be performed one to two weeks after initiation of spironolactone therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       Cyproterone acetate",
"      </a>",
"      is a progestin with antiandrogenic activity that is effective for the treatment of hirsutism. It is not available in the United States but is available in Canada and Mexico as a combination OCP containing ethinyl estradiol and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone",
"      </a>",
"      acetate (5 mg) (Diane&reg;). It also is available in Europe in this form and as a high-dose (50 mg) progestin tablet that can be combined with any form of estrogen.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       Flutamide",
"      </a>",
"      is a more specific antiandrogen with efficacy similar to that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone",
"      </a>",
"      . Its use has been limited by expense and the apparently idiosyncratic risk of fatal hepatocellular toxicity. Flutamide may permit ovulation in women with PCOS; however, its utility for this purpose is limited by the potential risk of feminization of the male fetus. The 2008 Endocrine Society Guidelines suggest against the routine use of flutamide because of its potential hepatotoxicity, expense, and the availability of other effective antiandrogens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"       \"Treatment of hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       Finasteride",
"      </a>",
"      interferes with androgen action by competitively inhibiting 5&alpha;-reductase, type 1. It has seemed slightly less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      in some studies on the treatment of women with hirsutism. However, metaanalysis of the limited available data has not shown a significant difference in efficacy between these treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/21\">",
"       21",
"      </a>",
"      ]. The usual dose is 5 mg daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion of these antiandrogens in the treatment of hirsutism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hirsutism\", section on 'Antiandrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OBESITY AND INSULIN RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121489830\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of obesity improves ovulation, acanthosis nigricans, androgen excess, and cardiovascular risk in patients with polycystic ovary syndrome (PCOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/1,4,22\">",
"     1,4,22",
"    </a>",
"    ]. Weight reduction is indicated as first-line therapy in obese patients with PCOS as part of a program to reduce cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/22\">",
"     22",
"    </a>",
"    ]. Diet and exercise are the first-line treatment for obese adolescents with PCOS as for obese individuals without PCOS. However, substantial changes in glycemic control or weight loss are difficult to achieve, even when an intensive lifestyle intervention program is undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/23\">",
"     23",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is combined with a behavior modification program [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/24\">",
"     24",
"    </a>",
"    ]. Bariatric surgery has led to improvement in hirsutism and androgen levels in the vast majority, and normalized menses in all adults reported to date; this option is currently limited in adolescents to select patients with extremely high body mass index (BMI) and access to highly specialized centers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"     \"Role of physical activity and exercise in obese adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is of major importance in the insulin resistance of PCOS, although insulin resistance is disproportionate to the degree of adiposity. Insulin resistance is commonly manifested as acanthosis nigricans and metabolic syndrome, although it may exist in the absence of these clinical findings. Insulin-resistant hyperinsulinism is an important extrinsic factor in the pathogenesis of PCOS and its complications. As a result, lowering the insulin levels in adolescents with PCOS may be beneficial. The biguanides, of which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is the only one available in the US are thus a potential adjunct in the treatment of PCOS; thiazolidinediones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ) also are effective in reducing insulin levels, but have raised safety concerns, as discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Thiazolidinediones'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=see_link&amp;anchor=H11771185#H11771185\">",
"     \"Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents\", section on 'Insulin resistant hyperinsulinism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although their mechanisms of action differ, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and thiazolidinediones reduce insulin concentrations, promote ovulation, and lower androgen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. These effects occur at lower doses than those necessary to affect steroidogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Whether they are effective in the absence of insulin resistance is disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents, however, are unlikely to normalize androgen levels that are substantially above normal, at best have a modest effect on hyperandrogenic symptoms, and their efficacy in promoting conception has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/33\">",
"     33",
"    </a>",
"    ]. These drugs alone provide endometrial protection only to the extent that ovulatory menstrual cycles result.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is the only one of these agents that we currently use in adolescents with PCOS because of concerns of weight gain and rare hepatic and possible cardiac toxicity with thiazolidinediones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main known biochemical action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is to reduce insulin levels primarily by directly inhibiting hepatic glucose output [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/25,34,35\">",
"     25,34,35",
"    </a>",
"    ]. It tends to suppress appetite and enhance weight loss. In adolescents with PCOS, metformin is used as an adjunct to management of obesity and the related insulin-resistant metabolic abnormalities. Its effectiveness is minimized in the absence of weight control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/36\">",
"     36",
"    </a>",
"    ], which may be why insulin levels are inconsistently lowered in treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/28,37,38\">",
"     28,37,38",
"    </a>",
"    ]. In adults, it also is used in promoting ovulation in patients who are resistant to fertility therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized, placebo-controlled trials in adolescents and adults have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    significantly increases the frequency of menses and ovulation (by about 50 percent), and lowers testosterone levels (by about 20 percent). However, the decrease in testosterone level is not enough to appreciably improve hirsutism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/28,37-39\">",
"     28,37-39",
"    </a>",
"    ]. The body mass index is modestly decreased, if at all. A small increase in high-density lipoprotein cholesterol levels also is reported.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is given, therapy is started with 500 mg daily before the evening meal, with an increase in the dose by 500 mg per week to the effective dose of 1500 to 2000 mg daily, as tolerated. The greater doses often are better tolerated when divided into two daily doses or when given in an extended release form (Glumetza&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/40\">",
"     40",
"    </a>",
"    ]. An effect cannot be anticipated before three months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/41\">",
"     41",
"    </a>",
"    ]. We suggest obtaining a comprehensive metabolic panel at baseline and every three to six months, or as necessary, because of the rare complication of lactic acidosis. Metformin is contraindicated in patients with impaired hepatic or renal function, alcoholism, or cardiopulmonary insufficiency because it can cause lactic acidosis in these settings.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    has been advocated by one group as a means of preventing PCOS when given prepubertally to girls at high risk for PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the results of such a recommendation have not been replicated outside of a unique population of girls from Barcelona and, even if effective, there is no reason to believe that the treatment does more than delay the onset of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones increase insulin sensitivity primarily by promoting lipid mobilization from the bloodstream via activation of peroxisome-proliferator-related receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/43\">",
"     43",
"    </a>",
"    ]. Troglitazone, the initial thiazolidinedione, decreased androgen levels in women with PCOS but has been withdrawn from the market in the United States and the United Kingdom because of the risk of hepatotoxicity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    is the safest of the newest generation of thiazolidinediones that are US Food and Drug Administration (FDA)-approved for treatment of type 2 diabetes mellitus. In small, randomized trials, this class of drugs appears to increase ovulation and decrease androgen levels. Unfortunately, these drugs also increase weight gain. Although pioglitazone is less toxic than troglitazone, a few cases have been reported of pioglitazone-induced reversible hepatic toxicity. Pioglitazone has been withdrawn from the market in France and Germany because of an association with bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H18#H18\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the limited data and concern for weight gain and hepatic toxicity, we do not recommend the use of thiazolidinediones in adolescents with PCOS unless they are indicated for diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Obesity and insulin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121489922\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with polycystic ovary syndrome (PCOS) are at increased risk of mood, anxiety disorders, and depression, and should be screened for these emotional disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Transsexualism prevalence may be increased in PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/46\">",
"     46",
"    </a>",
"    ]. Women with PCOS are also at risk for sleep-disordered breathing and should be screened accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link&amp;anchor=H34#H34\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Additional evaluation of PCOS patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20757812\">",
"    <span class=\"h1\">",
"     FAMILY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high frequency of polycystic ovary syndrome (PCOS) and metabolic syndrome among immediate relatives of individuals with PCOS, we recommend screening for features of metabolic syndrome and for diabetes mellitus in immediate family members of both sexes, particularly in those who are obese, and for features of PCOS in those females who are premenopausal. In particular, we suggest screening the parents of women with PCOS for diabetes using a two-hour oral glucose tolerance test because only about half are symptomatic at the time their daughter is diagnosed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link&amp;anchor=H1960542#H1960542\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Evaluation of family members'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several treatment options are available for adolescents with polycystic ovary syndrome (PCOS) (",
"    <a class=\"graphic graphic_table graphicRef67829 \" href=\"UTD.htm?4/54/4974\">",
"     table 1",
"    </a>",
"    ). The choice of therapy depends on the individual adolescent's symptoms, her goal for treatment, and preferences (eg, cost). In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of combination oral contraceptives as first-line treatment for adolescents who suffer the menstrual and cutaneous symptoms of PCOS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The progestin component inhibits endometrial proliferation, preventing hyperplasia and the associated risk of carcinoma. The estrogen component reduces excess androgen, which improves menstrual irregularity, dysfunctional uterine bleeding, hirsutism, and acne. We prefer the use of an oral contraceptive pill (OCP) that has antiandrogenic or minimal androgenic activity. As a general rule, OCPs should be continued until the patient is gynecologically mature (five years postmenarcheal) or has lost a substantial amount of excess weight. At this time, a trial off therapy is reasonable to document the persistence of the syndrome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Combination OCPs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the adolescent patient is unable or unwilling to take combination OCP, other therapeutic options for menstrual irregularities include progestin alone, low-dose glucocorticoid therapy, and gonadotropin releasing (GnRH) agonist therapy with add-back estrogen. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Progestin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Glucocorticoid therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'GnRH agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that hirsutism initially be treated by cosmetic and physical measures (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The choice is dependent on patient preference and includes shaving, bleaching, depilatory agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37652?source=see_link\">",
"       eflornithine",
"      </a>",
"      hydrochloride cream, electrolysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laser therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cosmetic and physical measures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link\">",
"       \"Removal of unwanted hair\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of acne is the same as in patients without PCOS and is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link\">",
"       \"Treatment of acne vulgaris\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that OCPs be the initial pharmacologic agents used in treating patients with hirsutism who fail to respond adequately to cosmetic and dermatologic measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For substantial improvement, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      , which should only be used in combination with OCPs (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Medical therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"       \"Treatment of hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight loss in obese adolescents with PCOS improves ovulation, acanthosis nigricans, and hyperandrogenemia. Weight-reduction measures (eg, exercise and diet) are the same as in obese patients without PCOS. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Obesity and insulin resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin-lowering agents improve ovulation in about half of cases, and modestly reduce androgen levels [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24297/abstract/17,48\">",
"       17,48",
"      </a>",
"      ]. They are not as effective as OCPs in controlling menstrual cyclicity or hirsutism.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      is the only one of these agents that we use in adolescents with PCOS, and is used as an adjunct to weight-control measures and to treat co-existent insulin-resistant metabolic abnormalities. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Insulin resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"       \"Metformin for treatment of the polycystic ovary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/1\">",
"      Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/2\">",
"      Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/3\">",
"      Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab 2011; 96:3675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/4\">",
"      Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/5\">",
"      Cremer M, Phan-Weston S, Jacobs A. Recent innovations in oral contraception. Semin Reprod Med 2010; 28:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/6\">",
"      Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 342:d2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/7\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/8\">",
"      Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004; 364:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/9\">",
"      Woods KS, Reyna R, Azziz R. Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. Fertil Steril 2002; 77:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/10\">",
"      Bagis T, Gokcel A, Zeyneloglu HB, et al. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab 2002; 87:4536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/11\">",
"      Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/12\">",
"      Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/13\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/14\">",
"      Azziz R, Black VY, Knochenhauer ES, et al. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab 1999; 84:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/15\">",
"      Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab 2000; 85:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/16\">",
"      Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med 2010; 28:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/17\">",
"      Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/18\">",
"      Shapiro J. Clinical practice. Hair loss in women. N Engl J Med 2007; 357:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/19\">",
"      van Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment of acne in women. Am J Clin Dermatol 2004; 5:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/20\">",
"      Ib&aacute;&ntilde;ez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000; 85:3251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/21\">",
"      Swiglo BA, Cosma M, Flynn DN, et al. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/22\">",
"      Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/23\">",
"      Freemark M. Management of adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/24\">",
"      Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011; 95:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/25\">",
"      Geller DH, Pacaud D, Gordon CM, et al. State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). Int J Pediatr Endocrinol 2011; 2011:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/26\">",
"      Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/27\">",
"      Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; :CD003053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/28\">",
"      Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/29\">",
"      Mansfield R, Galea R, Brincat M, et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003; 79:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/30\">",
"      Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase. J Biol Chem 2001; 276:16767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/31\">",
"      Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/32\">",
"      Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2006; 91:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/33\">",
"      Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/34\">",
"      Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/35\">",
"      He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/36\">",
"      Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/37\">",
"      Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/38\">",
"      Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/39\">",
"      Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008; 93:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/40\">",
"      Schwartz SL, Wu JF, Berner B. Metformin extended release for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/41\">",
"      August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab 2008; 93:4576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/42\">",
"      Ib&aacute;&ntilde;ez L, L&oacute;pez-Bermejo A, D&iacute;az M, et al. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 2011; 96:E1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/43\">",
"      Yki-J&auml;rvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/44\">",
"      Dokras A. Mood and anxiety disorders in women with PCOS. Steroids 2012; 77:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/45\">",
"      Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/46\">",
"      Baba T, Endo T, Ikeda K, et al. Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan. J Sex Med 2011; 8:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/47\">",
"      Ehrmann DA. Metabolic dysfunction in pcos: Relationship to obstructive sleep apnea. Steroids 2012; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24297/abstract/48\">",
"      Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 2003; 101:785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5853 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24297=[""].join("\n");
var outline_f23_46_24297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MENSTRUAL IRREGULARITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Combination OCPs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Progestin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dysfunctional uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CUTANEOUS HYPERANDROGENISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cosmetic and physical measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Combination OCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antiandrogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OBESITY AND INSULIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H121489830\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H121489922\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20757812\">",
"      FAMILY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5853|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/12/36035\" title=\"figure 1\">",
"      Grading of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/54/4974\" title=\"table 1\">",
"      Medications for PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34970?source=related_link\">",
"      Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=related_link\">",
"      Gonadotropin releasing hormone agonists for long-term treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=related_link\">",
"      Removal of unwanted hair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24266?source=related_link\">",
"      Treatment of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_46_24298="Intracoronary stent restenosis";
var content_f23_46_24298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracoronary stent restenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/46/24298/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/46/24298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracoronary stents reduce the rate of angiographic and clinical restenosis and periprocedural myocardial infarction compared to percutaneous transluminal coronary angioplasty (PTCA) alone. As a result, stents are currently utilized in nearly all percutaneous coronary interventions (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intracoronary stent restenosis (ISR) and its treatment will be reviewed here. The possible role of medical therapies to prevent restenosis, and other complications of stenting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29081?source=see_link\">",
"     \"Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1558346535\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a successful procedure, coronary stents can fail to maintain vessel patency due to either restenosis or stent thrombosis.&nbsp;Restenosis is a gradual re-narrowing of the stented segment that occurs mostly between 3 to 12 months after stent placement. It usually presents as recurrent angina but can present as acute MI in approximately 10 percent of patients.&nbsp;It can usually be managed by repeat percutaneous revascularization.",
"   </p>",
"   <p>",
"    In contrast, stent thrombosis is an abrupt thrombotic occlusion of a previously widely patent stent.&nbsp;It is a catastrophic complication that presents as sudden death or large myocardial infarction in most patients.&nbsp;Despite successful repeat revascularization, the six-month mortality is high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this topic, intracoronary stent restenosis and in-stent restenosis refer to the same issue.",
"   </p>",
"   <p>",
"    The following are widely agreed upon definitions related to intracoronary stent restenosis (ISR) (",
"    <a class=\"graphic graphic_table graphicRef56696 \" href=\"UTD.htm?37/15/38140\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restenosis &ndash; A reduction in lumen diameter after PCI due to arterial damage and subsequent neointimal tissue proliferation.",
"     </li>",
"     <li>",
"      Binary angiographic restenosis &ndash; A &ge;50 percent luminal narrowing at follow-up angiography.",
"     </li>",
"     <li>",
"      Clinical restenosis &ndash; The presence of both binary angiographic restenosis and clinical symptoms or signs of ischemia (either at rest or with stress) OR restenosis with a &ge;70 percent reduction in lumen diameter even in the absence of clinical symptoms or signs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE OF RESTENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major trials published in 1994, STRESS and Benestent, evaluated the first generation Palmaz-Schatz (bare metal) coronary stent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The angiographic restenosis rate at six months after successful stent placement was significantly lower than with PTCA alone (32 versus 42 percent and 22 versus 32 percent, respectively). However, the type of lesions studied in these trials were focal, simple stenoses in a vessel &gt;3 mm, and higher absolute rates of stent restenosis are seen in some lesion types, such as long lesions or small vessels, or with stenting of multiple lesions. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Stenting of multiple lesions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Long lesions or diffuse disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Small coronary arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subsequent pooled analysis of 6186 patients from six major clinical trials assessed second generation bare-metal stents. The frequency of clinical restenosis was defined as target lesion or target vessel revascularization beyond 30 days, death, or MI in the target vessel territory [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/4\">",
"     4",
"    </a>",
"    ]. The stenting protocol in each study included high-pressure postdilation and antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and, for four weeks,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one year, target lesion revascularization was performed in 12.0 percent and target vessel revascularization in 14.1 percent. These values were more than two-thirds higher than those at six months (6.9 and 8.0 percent), demonstrating a more delayed presentation than had been appreciated.",
"     </li>",
"     <li>",
"      Angiographic restenosis was not equivalent to clinical restenosis. Clinically relevant restenosis occurred in only about one-half of patients with angiographic restenosis (defined as &ge;50 percent diameter stenosis). This was mostly a matter of degree since 50 to 70 percent angiographic stenosis is unlikely to cause symptoms. The incidence of target lesion revascularization was much higher with more than 70 percent diameter stenosis (73 versus 26 percent for less than 60 percent diameter stenosis). The predictors of both clinical and angiographic restenosis were the same (smaller posttreatment lumen diameter, stent length, and diabetes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinically significant restenosis with second generation bare-metal stents is a relatively early event, most often becoming clinically evident within the first 6 to 12 months after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/5\">",
"     5",
"    </a>",
"    ]. After one year, recurrent ischemia is more likely to be due to new or progressive disease at another site rather than restenosis. The magnitude of this difference was illustrated in a review of 1228 patients who were followed for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/5\">",
"     5",
"    </a>",
"    ]. After the first year, the annual hazard rate was 1.7 percent for target lesion events compared to 6.3 percent for nontarget lesion events.",
"   </p>",
"   <p>",
"    Clinical trial data represent an underestimate of true risk given the favorable lesion characteristics in these studies. Restenosis rates are considerably higher in more complex lesion subsets, such as small vessels, long lesions, and bifurcations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"     \"Use of intracoronary stents for specific coronary lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Drug-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of in-stent restenosis (ISR) has been reported between 3 to 20 percent, depending on which drug-eluting stent is evaluated, the duration of follow-up, and the complexity of the lesions in which the stents were placed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/1\">",
"     1",
"    </a>",
"    ]. The following three studies provide representative outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the j-Cypher registry of nearly 13,000 patients who received a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stent, the cumulative incidence of target lesion revascularization (TLR) within the first year was 7.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/6\">",
"       6",
"      </a>",
"      ]. TLR continued to occur at a rate of 2.2 percent per year, such that the rate was 15.9 percent at five years.",
"     </li>",
"     <li>",
"      In the Endeavor IV trial, 1548 patients were randomly assigned to either a zotarolimus eluting stent or a PES. At three years, the rates of target lesion revascularization were 6.5 and 6.1 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link&amp;anchor=H10#H10\">",
"       \"Comparison of drug-eluting intracoronary stents\", section on 'Zotarolimus-eluting stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the SIRTAX LATE study, 1012 patients were randomly assigned to either SES or PES [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/8\">",
"       8",
"      </a>",
"      ]. In an analysis of the 444 patients who underwent repeat angiography, the cumulative five-year rates of target lesion revascularization were 13.1 and 15.1 percent, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link&amp;anchor=H71604313#H71604313\">",
"       \"Comparison of drug-eluting intracoronary stents\", section on 'Sirolimus and paclitaxel stents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple trials have demonstrated that both first generation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    drug-eluting stents and second generation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    and zotarolimus drug-eluting stents markedly reduced the incidence of ISR and the rate of target lesion revascularization by about 75 percent. The data supporting this conclusion are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These benefits have been consistent across subgroups, including longer lesions, smaller vessels, and diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"     \"Use of intracoronary stents for specific coronary lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The restenosis benefits of drug-eluting stents must be balanced against a slight but important increased risk for stent thrombosis beyond one year (in patients treated with early generation DES) and the associated requirement for prolonged dual antiplatelet therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H6#H6\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Drug-eluting stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accordingly, the benefits of drug-eluting stents on restenosis must be weighed against rates of stent thrombosis, which often lead to death or MI, if dual antiplatelet therapy is prematurely discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the marked reductions in restenosis and target lesion revascularization with drug-eluting stents, intracoronary radiation is now infrequently used to prevent restenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=see_link\">",
"     \"Use of intracoronary radiation to prevent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many of the issues related to drug-eluting stents can be discussed as a class effect, it is also important to consider potential differences between devices in terms of effectiveness of restenosis prevention, possible late &ldquo;catch-up&rdquo; or loss of effectiveness, and safety consideration of risk for stent thrombosis. These topics are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction in lumen diameter following stent implantation is the result of arterial damage with subsequent neointimal tissue proliferation. Typically, neointimal proliferation is distributed uniformly along the length of the stent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], but may also be relatively focal. The neointimal proliferation occurs in association with macrophage accumulation and extensive neovascularization, suggesting a role for organization of mural thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with this hypothesis are the pathologic findings in 55 stents in 35 coronary arteries from patients who died, had repeat coronary artery bypass graft surgery (CABG), or underwent transplantation; the mean duration of stent placement was 39 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/13\">",
"     13",
"    </a>",
"    ]. The following abnormalities were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrin, platelets, and neutrophils, indicating thrombus formation and acute inflammation, have been demonstrated at stent struts evaluated &le;11 days after placement; inflammation was more pronounced in struts that were embedded in a lipid core and those in contact with damaged media.",
"     </li>",
"     <li>",
"      Stents evaluated at a later time showed neointimal growth that increased as the ratio of stent area to reference lumen area increased; neointimal thickness was greater for struts associated with medial damage than for those in contact with plaque. Over time, extracellular matrix accumulation may play a greater role than cell proliferation in neointimal thickening [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is an increase in neointimal tissue with subsequent reduction in the minimal luminal diameter during the first six months after stent placement, there may be no further reduction in luminal diameter, or even regression, at one year and a further increase in diameter at later time points [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Serial angiography and angioscopy found the following sequence of changes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/16\">",
"     16",
"    </a>",
"    ]. There was initial thickening of the neointima that became nontransparent at six months; thereafter, the neointima became thin and transparent, ie, the majority of the stent was visible. This correlated with an increase in the luminal diameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1558346569\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms to explain the observations of inflammation, mural thrombus, and neointimal tissue growth include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biologic factors, such as resistance to the drug component of stents",
"     </li>",
"     <li>",
"      Hypersensitivity",
"     </li>",
"     <li>",
"      Mechanical factors such as stent underexpansion or stent fracture",
"     </li>",
"     <li>",
"      Technical factors such as barotrauma outside the stented segment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patterns of restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns of ISR have been described as focal or diffuse. However, in order to further classify the types of restenosis, an angiographic classification was developed in a study of 288 ISR lesions in 245 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pattern I describes a focal (&lt;10 mm in length) lesion and was found in 42 percent of patients; subsequent target lesion revascularization was performed in 19 percent of patients.",
"     </li>",
"     <li>",
"      Pattern II describes ISR &gt;10 mm within the stent and was present in 21 percent of patients; 35 percent required target lesion revascularization.",
"     </li>",
"     <li>",
"      Pattern III describes in-stent stenosis &gt;10 mm extending outside the stent; target lesion revascularization performed in 50 percent of patients.",
"     </li>",
"     <li>",
"      Pattern IV describes a totally occluded stent, which was found in 7 percent of patients; 83 percent underwent target lesion revascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREDICTORS OF RESTENOSIS IN BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 1084 patients who underwent follow-up angiography six months after bare-metal stent placement, the incidence of restenosis was as low as 16 percent in the absence of any risk factors (diabetes, multiple stents, and minimal luminal diameter after stenting &lt;3 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/19\">",
"     19",
"    </a>",
"    ], and as high as 59 percent when at least three factors were present (",
"    <a class=\"graphic graphic_figure graphicRef78635 \" href=\"UTD.htm?1/14/1262\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Angiographic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of angiographic risk factors have been identified for stent restenosis, mostly with bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/4,20-29\">",
"     4,20-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"     \"Use of intracoronary stents for specific coronary lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restenotic target lesion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Longer stented stenosis length and stent length [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Smaller vessel size",
"     </li>",
"     <li>",
"      Ostial lesion location",
"     </li>",
"     <li>",
"      Preinterventional lesion site plaque burden",
"      <span class=\"nowrap\">",
"       (plaque/total",
"      </span>",
"      arterial area) and amount of residual plaque burden after stent implantation",
"     </li>",
"     <li>",
"      Use of coil stents [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Longitudinal straightening effect and poststent changes in vessel angulation &ge;9.1&ordm; [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Minimal lumen diameter &lt;3 mm at the end of the procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of the BENESTENT I, BENESTENT II pilot, BENESTENT II, and MUSIC trials found that the restenosis rate after bare-metal stenting of short de novo lesions (&lt;15 mm) could be predicted best by two variables obtained from quantitative coronary angiography: postprocedural percent diameter stenosis, and vessel size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/27\">",
"     27",
"    </a>",
"    ]. Obtaining a large luminal area (&gt;8 mm",
"    <sup>",
"     2",
"    </sup>",
"    ) reduces the probability of restenosis by allowing more hyperplasia to develop before restenosis (defined as a &gt;50 percent diameter narrowing) is reached.",
"   </p>",
"   <p>",
"    Similar findings were noted in the pooled analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/4\">",
"     4",
"    </a>",
"    ]. Among patients who underwent routine angiographic follow-up (at a mean of 202 days after the procedure), the likelihood of requiring target vessel revascularization was significantly greater in patients with diameter stenosis &gt;70 percent (73 versus 26 percent for &lt;60 percent diameter stenosis). Other risk factors were smaller pretreatment and final minimal lumen diameter, longer stent length, diabetes, UA, and hypertension.",
"   </p>",
"   <p>",
"    Excessive stent length for the length of the lesion also appears to increase the risk of restenosis. This was illustrated in a meta-analysis of data from 1181 patients in six major trials of bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/30\">",
"     30",
"    </a>",
"    ]. The mean lesion length was 12.4 mm, while the mean stent length was 20.0 mm; stent length exceeded lesion length in 87 percent of lesions. The risk of binary restenosis was 20, 27, and 35 percent for stents that matched lesion length or that exceeded lesion length by 10 or 20 mm, respectively. Excess stent length significantly increased the risk of target lesion revascularization (adjusted odds ratio 1.12 per 10 mm; 95% CI 1.02-1.24).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Late lumen loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late lumen loss, which is due to in-stent neointimal hyperplasia, is defined as the difference between the minimum lumen diameter immediately after stenting and the minimum lumen diameter at six to eight month angiographic follow-up. It is an important predictor of the risk of clinical restenosis with both bare-metal and drug-eluting stents and appears to be more reliable than binary angiographic restenosis (&gt;50 percent diameter stenosis at follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical trials that demonstrated lower target lesion revascularization rates with drug-eluting compared to bare-metal stents also found significantly lower rates of late lumen loss with drug-eluting stents (eg, 0.17 versus 1.00 mm in SIRIUS and 0.39 versus 0.92 mm in TAXUS IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Incremental changes in late lumen loss between 0 and 1 mm are associated with an increasing risk of clinical restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of bare-metal stenting identified a number of independent clinical predictors of stent restenosis and the need for target vessel revascularization, including female sex, diabetes, hypertension, weight and body mass index, multivessel disease, and the use of multiple stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/4,20-22,29\">",
"     4,20-22,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cigarette smokers require target lesion revascularization significantly less frequently than nonsmokers (6.6 versus 10.1 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Despite this difference in clinical restenosis, the angiographic restenosis rate does not differ between the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/36,38\">",
"     36,38",
"    </a>",
"    ], and the rates of subsequent death and MI are significantly higher for smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/37\">",
"     37",
"    </a>",
"    ]. Explanations for this paradox include a reduced sensitivity to restenosis or a greater reluctance to seek medical attention for recurrent angina in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Contact allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A contact allergy to metal compounds, particularly nickel, released from stainless steel stents may contribute to the development of stent restenosis, although the evidence for this is limited. Studies evaluating the association between metal allergy and stent restenosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34342?source=see_link\">",
"     \"Nickel hypersensitivity and coronary artery stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Strut thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strut thickness may influence the development of stent restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. This was evaluated in the ISAR-STEREO trial in which 651 patients with lesions in vessels &gt;2.8 mm in diameter were randomly assigned to a bare-metal stent with a thin (50 &micro;m) or thick (140 &micro;m) strut; both stents were of similar design [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/39\">",
"     39",
"    </a>",
"    ]. At six months, the thin strut group had a significantly lower incidence of angiographic restenosis (15 versus 26 percent for the thick strut, relative risk 0.58) and a lesser likelihood of reintervention for clinical restenosis (8.6 versus 13.8 percent, relative risk 0.62).",
"   </p>",
"   <p>",
"    The companion ISAR-STEREO-2 trial compared the same stent geometry, fabricated with either thin or thick (140 &micro;M) struts in 611 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/40\">",
"     40",
"    </a>",
"    ]. Procedural success was &ge;99 percent in both groups, but device success was lower with the thin stent (87 versus 99 percent with the thick stent). The thin stent was associated with significant reductions in angiographic restenosis at six months (18 versus 31 percent) and target vessel revascularization at one year (12 versus 22 percent). There was no difference in the combined endpoint of death or MI at one year.",
"   </p>",
"   <p>",
"    The significance of the independent effect of strut thickness on restenosis must await more detailed analyses from these and other studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technical problems associated with stent deployment contribute to restenosis in a significant number of patients. In a review of 1090 patients with restenosis in bare-metal stents who underwent IVUS, mechanical complications were considered to contribute in 4.5 percent, while an additional 20 percent had stent underexpansion as a contributing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/42\">",
"     42",
"    </a>",
"    ]. These findings highlight the need for optimal stenting, as with the use of high pressure balloon dilation with or without IVUS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of the use of intracoronary stents\", section on 'Optimal stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lesion morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphology of the coronary lesion also may have predictive value. In 1988, a joint committee of the",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    published a classification of anatomic patterns that correlated with success and complication rates for PTCA. Lesions were divided into three categories according to the risk of complications and restenosis and the rate of success (",
"    <a class=\"graphic graphic_table graphicRef80401 \" href=\"UTD.htm?26/35/27196\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A lesions &mdash; high success and low restenosis rate",
"     </li>",
"     <li>",
"      Type B lesions &mdash; intermediate success and moderate risk of restenosis; this has been further modified to type B1 (one adverse type B characteristic) and type B2 (more than one type B characteristic) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Type C lesions &mdash; low success and high risk of restenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification also may correlate with the incidence of angiographic restenosis at six months after coronary stent placement. In one large series of bare-metal stenting, the overall restenosis rate was 33 percent for complex lesions (type B2 and C) and 25 percent for simple lesions (type A and B1; p &lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intravascular ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVUS has been used to evaluate coronary artery anatomy and size before and after stenting. In one series of 291 patients, the most consistent IVUS predictor of angiographic ISR at 5.5 months was final lumen dimension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/26\">",
"     26",
"    </a>",
"    ]. Analysis of data from five trials that used IVUS guidance during bare-metal stenting (MUSIC, WEST-II, ESSEX, ERASER, and TRAPIST) found that predictors of ISR were minimum in-stent area, stent length, and in-stent diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stenting of multiple lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who undergo stent placement in multiple lesions, the restenosis rate appears to be higher for a lesion when a companion lesion develops restenosis. One study evaluated 1244 patients who underwent stent placement in 1734 lesions; the restenosis rate for single, double, or &ge;3 lesion stenting was 24, 29, and 34 percent, respectively, on a per lesion basis and 24, 44, and 63 percent, respectively, on a per patient basis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/46\">",
"     46",
"    </a>",
"    ]. The risk of a lesion developing restenosis was 2.5 times higher if a companion lesion had restenosis, an effect that was independent of all other clinical factors associated with restenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H5#H5\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Multivessel revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with even mild chronic kidney disease are at increased risk for coronary heart disease. Chronic kidney disease is also a risk factor for adverse outcomes in patients who undergo stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this effect was illustrated in a series of over 5300 patients who underwent bare-metal stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/47\">",
"     47",
"    </a>",
"    ]. Both in-hospital and one-year mortality were significantly associated with kidney function. One-year mortality was 1.5 percent when the estimated creatinine clearance was 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or more compared to 3.6, 7.8, and 18.3 percent at creatinine clearances of 50 to 69, 30 to 49, and less than 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively. The mortality risk was largely independent of other risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H24#H24\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Prognosis after PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84738363\">",
"    <span class=\"h1\">",
"     PREDICTORS IN DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although restenosis is significantly less common with drug-eluting stents (DES) than bare-metal stents (BMS), it still occurs at a rate between 5 and 15 percent depending on the duration of follow-up and the complexity of the initial lesion. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Drug-eluting stents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical predictors appear to play a less relevant role in restenosis with DES compared to BMS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an angiographic follow-up study of 238 patients who underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stent (SES) placement in complex lesions, the following characteristics were identified as independent multivariate predictors of angiographic restenosis: treatment of in-stent restenosis (odds ratio [OR] 4.16); ostial location (OR 4.84); diabetes (OR 2.63); total stented length (per 10-mm increase, OR 1.42); reference diameter (per 1.0-mm increase, OR 0.46); and left anterior descending artery (OR 0.30) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another angiographic follow-up study of 1845 patients who underwent implantation of either SES or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stent (PES), the following were found to be independent multivariate predictors of angiographic restenosis: vessel size (per 0.5 mm decrease, OR 1.74, 95% CI 1.31-2.32); final diameter stenosis (per 5 percent increase, OR 1.30, 95% CI 1.15-1.47); SES compared to PES (0.60, 95% CI 0.44-0.81) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential risk factors for restenosis with SES were evaluated in an analysis from the RESEARCH study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/24\">",
"     24",
"    </a>",
"    ]. Among 238 patients who underwent six-month angiographic follow-up, in-segment restenosis occurred in 7.9 percent (6.3 percent in-stent, 0.9 percent at the proximal edge, and 0.7 percent at the distal edge). The following factors were identified as multivariate predictors of restenosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of in-stent restenosis &mdash; restenosis rate 19.6 percent",
"     </li>",
"     <li>",
"      Ostial lesion location &mdash; 14.7 percent",
"     </li>",
"     <li>",
"      Diabetes mellitus &mdash; 14.3 percent",
"     </li>",
"     <li>",
"      Stented length &gt;36 mm &mdash; 13.9 percent",
"     </li>",
"     <li>",
"      Reference vessel diameter &lt;2.17 mm &mdash; 10.3 percent",
"     </li>",
"     <li>",
"      Vessel other than left anterior descending coronary artery &mdash; 10.8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS OF IN-STENT RESTENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the rates of ISR and target lesion revascularization are much lower with drug-eluting stents than bare-metal stents, although the rate of late stent thrombosis may be higher, particularly if dual antiplatelet therapy is not continued as prescribed. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Drug-eluting stents'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H20#H20\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Late and one-year cumulative stent thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H12#H12\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Very late stent thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Restenosis is primarily suspected by the presence of recurrent symptoms that are more likely to be stable than at initial presentation. Nevertheless, an appreciable proportion of patients can present with an acute coronary syndrome. In a review of 1186 cases of ISR with bare-metal stents from the Cleveland Clinic, 9.5 percent presented as an acute myocardial infarction (2.2 percent with ST segment elevation) and 26.4 percent with unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/50\">",
"     50",
"    </a>",
"    ]. In two smaller series, the incidence of restenosis presentation as acute myocardial infarction ranged from 3.5 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similarly high frequency of acute coronary syndrome (mostly unstable angina) has been noted with restenosis in drug-eluting stents. In two small reports of patients with DES restenosis, 27 and 50 percent presented with a diagnosis of unstable angina pectoris and 5 and 11 percent presented with MI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of ISR is confirmed by coronary angiography, usually performed as a prelude to repeat catheter-based therapy in the same sitting. Noninvasive coronary angiography is still an investigational approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link&amp;anchor=H36#H36\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\", section on 'Coronary artery stents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ISR is much less common with the use of drug-eluting stents, the sheer number of stents being implanted in current interventional practice means that the treatment of ISR remains an important clinical challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Indications for intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for angiography and repeat revascularization rather than medical therapy alone (eg, antianginal and secondary prevention therapies) in patients with prior stenting and stable angina are similar to those for patients without prior intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H12#H12\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'PCI versus medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When revascularization is indicated, percutaneous approaches are most often used rather than bypass surgery. Based upon the data presented in the following sections, we use a drug-eluting stent in the majority of patients for restenosis treatment of bare-metal stents. The most appropriate treatment for restenosis of drug-eluting stents remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Percutaneous coronary intervention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since restenosis of any type of stent is commonly due to underexpansion at the time of initial deployment, IVUS is considered by many experts essential in the majority of cases to evaluate the restenotic stent as well as the possible involvement of the peri-stent areas. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Mechanical problems'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performed for stent restenosis, balloon angioplasty (PTCA) alone results in both additional stent expansion and tissue extrusion out of the stent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/55\">",
"     55",
"    </a>",
"    ]. Older studies demonstrated the efficacy of PTCA for restenosis, with the best results seen with focal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/51,56\">",
"     51,56",
"    </a>",
"    ]. However, there was an appreciable rate of recurrent restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/51,57,58\">",
"     51,57,58",
"    </a>",
"    ] and PTCA alone has largely been supplemented by adjunctive repeat stenting, with drug-eluting stents. Balloon angioplasty alone, however, remains the initial step of the procedure and is necessary to achieve proper expansion of the initially implanted stent. There appears to be no value of using a second bare-metal stent in the setting of ISR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Repeat stenting in bare-metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat stenting using a DES (stenting within the original stent) is the preferred approach for treating stent restenosis. Initial observations with bare-metal stents (eg, the RIBS-I trial) showed variable efficacy in relation to PTCA alone that was related in part to vessel size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion will emphasize the use of drug-eluting stents for restenosis in bare-metal stents. The more limited data on the management on restenosis in drug-eluting stents is presented in the next section. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of drug-eluting stent restenosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of observational studies, mostly small, suggested benefit from the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents for ISR of bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/24,62-65\">",
"     24,62-65",
"    </a>",
"    ]. This benefit was confirmed in randomized trials. In the ISAR-DESIRE trial, 300 patients with ISR were randomly assigned to treatment with a sirolimus stent, a paclitaxel stent, or balloon angioplasty alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/66\">",
"     66",
"    </a>",
"    ]. The primary endpoint was angiographic &ge;50 percent restenosis at six months. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binary angiographic restenosis was significantly less common with a drug-eluting stent compared to angioplasty alone: 14.3 percent with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent; 21.7 percent with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stent; and 44.6 percent with balloon angioplasty. The relative risks compared to balloon angioplasty were 0.32 and 0.49 with the sirolimus and paclitaxel stents. The difference between the sirolimus and paclitaxel stents did not reach statistical significance, but the degree of late lumen loss was significantly lower with the sirolimus stent (0.32 versus 0.55 mm).",
"     </li>",
"     <li>",
"      The respective rates of target vessel revascularization were 8, 19, and 33 percent in the three groups. Secondary analysis revealed that the difference between the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stents was statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar short-term benefits from a drug-eluting stent were noted in the RIBS-II trial in which 150 patients with ISR were randomly assigned to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stent or balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/67\">",
"     67",
"    </a>",
"    ]. At nine-month angiographic follow-up, the sirolimus stent was associated with significant reductions in the rate of recurrent restenosis (11 versus 39 percent) and target vessel revascularization (11 versus 30 percent). Event-free survival (death, MI, and target vessel revascularization) was significantly better with the sirolimus-eluting stent at one and four years (88 versus 69 and 76 versus 65 percent respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    stents also appear to produce good outcomes in patients with complex ISR as defined by diffuse or proliferative lesions or total occlusion. In a series of 161 such lesions in 136 patients, the nine-month rates of in-stent binary restenosis and target vessel revascularization were 17 and 8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of treatment of ISR with SES appear to be maintained long term. In a report from a registry of 233 patients with bare-metal stent restenosis treated with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    eluting stent, target lesion revascularization occurred in 11.1 and definite or possible stent thrombosis in 2.8 percent of patients at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H4#H4\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Timing and incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update for PCI and the 2005 European Society of Cardiology (ESC) Task Force for PCI concluded that the weight of evidence is in favor of efficacy of drug-eluting stents for ISR whether the initial stent was a bare-metal or a drug-eluting stent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. This approach was not changed in the 2009 focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Intracoronary radiation versus drug-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracoronary radiotherapy (IRT or brachytherapy) has been used as an adjunctive treatment for ISR, regardless of the mechanical method used for treatment (balloon PTCA, additional stent implantation, or specialized revascularization device). However, brachytherapy is rarely used clinically.",
"   </p>",
"   <p>",
"    In early controlled trials, both beta and gamma radiation reduced the chance of subsequent recurrence by 40 to 50 percent compared to mechanical treatment (not using drug-eluting stents) alone, but the late failure rate was as high as 20 to 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of intracoronary radiation to prevent restenosis\", section on 'Use for in-stent restenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two more recent trials comparing intracoronary brachytherapy and drug-eluting stents demonstrate the relative advantage of the latter therapy in patients with bare-metal stent restenosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TAXUS V ISR trial (396 patients),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      -eluting stents were associated with a significant reduction in ischemia-driven target vessel revascularization (18.1 versus 27.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In SISR (384 patients),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stents were associated with significant reductions at nine months in angiographic restenosis (19.8 versus 29.5 percent, relative risk 0.67) and target lesion revascularization (8.5 versus 19.2 percent, relative risk 0.43) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presumed mechanism of benefit is greater acute gain with stent placement combined with a similar or reduced rate of late lumen loss [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Treatment of drug-eluting stent restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stent restenosis is becoming an increasingly frequent problem given the large number of patients in whom they have been placed. There have been few reports addressing the management of this problem and no randomized trials have compared treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/53,78-81\">",
"     53,78-81",
"    </a>",
"    ]. Thus, the optimal approach is not certain.",
"   </p>",
"   <p>",
"    In a two-year follow-up of patients enrolled in the SIRIUS trial, 22 of 533 patients (4 percent) had ischemia driven target lesion revascularization with the first year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/79\">",
"     79",
"    </a>",
"    ]. Treatment was at the operator's discretion and included bare-metal stent implantation, balloon dilatation, or intravascular brachytherapy. At one-year follow-up after the first recurrence, five patients (23 percent) required a repeat revascularization procedure.",
"   </p>",
"   <p>",
"    There are limited data regarding the safety and effectiveness of a second DES for DES restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/53,81\">",
"     53,81",
"    </a>",
"    ]. The following observational studies attempted to address this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 116 patients with restenosis of either a PES or SES, repeat stenting with a DES was safe but associated with a high rate of target vessel revascularization (29 percent at one year) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/81\">",
"       81",
"      </a>",
"      ]. The rate was similar whether the same or alternative DES was used for the repeat procedure.",
"     </li>",
"     <li>",
"      In a report from the j-Cypher registry of 966 patients in whom an SES had been placed, outcomes were compared between 537 restenotic lesions treated with an SES and 557 treated with balloon dilatation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/82\">",
"       82",
"      </a>",
"      ]. The cumulative incidence of recurrent target lesion revascularization in the SES treated restenosis lesions was significantly lower than that in the balloon angioplasty treated lesions (23.8 versus 37.7 percent) at two-year follow-up.",
"     </li>",
"     <li>",
"      In the ISAR-DESIRE 2 trial, 450 patients with clinically significant restenosis of an SES were randomly assigned to either SES or PES [",
"      <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/83\">",
"       83",
"      </a>",
"      ]. There was no significant difference in the rate of the primary outcome of late lumen loss between the two stents, nor were there differences in the rates of target lesion revascularization or the composite of death or myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is insufficient evidence to recommend any specific treatment for DES restenosis, repeat stenting with a DES is currently performed in many institutions. We perform IVUS in most patients with DES restenosis prior to making a decision about the revascularization procedure. For those patients in whom a poorly expanded stent is found, stent expansion optimized by repeat balloon angioplasty should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Drug-coated balloon angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies using angioplasty balloons coated with antiproliferative drugs in de novo lesions failed to demonstrate efficacy for the prevention of intracoronary restenosis. However, this technique may have application for the treatment of ISR, in part because of concerns for the creation of multiple stent layers",
"   </p>",
"   <p>",
"    In an early study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -coated balloons significantly reduced in-segment late luminal loss compared to uncoated balloons when used in patients with ISR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/84\">",
"     84",
"    </a>",
"    ]. The results were better than those obtained using first generation drug-eluting stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/66,74,76\">",
"     66,74,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a more recent study, 131 patients with in-stent (BMS) restenosis were randomly assigned to either a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -coated balloon or a paclitaxel-eluting stent (PES) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/85\">",
"     85",
"    </a>",
"    ]. At six months, the paclitaxel-coated balloon significantly reduced the primary endpoint of in-segment late lumen loss compared with the PES (0.17 versus 0.38 mm respectively). At 12 months there was a nonsignificant trend toward a lower rate of major adverse cardiac events (target lesion revascularization, stent thrombosis, myocardial infarction, and death) with the coated-balloon (9 and 22 percent). This difference seen was attributable principally to a lower rate of target lesion revascularization with the coated balloon (6 versus 15 percent).",
"   </p>",
"   <p>",
"    The efficacy of drug-eluting balloon angioplasty for patients with DES restenosis (of at least 50 percent) was evaluated in the ISAR-DESIRE 3 trial, which randomly assigned 402 patients (with 500 lesions) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting balloons (PEB), PES, or balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/86\">",
"     86",
"    </a>",
"    ]. Nearly half the patients were initially treated with a second generation stent. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    indefinitely and a platelet P2Y12 receptor blocker was given for six months. There was no significant difference in the rate of the primary end point of diameter stenosis at six- to eight-month angiographic follow-up between PEB and PES (38.0 versus 37.4 percent). PEB and PES were superior to balloon angioplasty alone (54.1 percent; p for superiority &lt;0.0001 for both comparisons).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Specialized revascularization devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional PCI with drug-eluting stents has markedly diminished the use of specialized revascularization devices, such as rotational or directional atherectomy, and laser angioplasty. The data evaluating the use of these procedures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H22#H22\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Atherectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update for PCI concluded that there were no long-term studies demonstrating clinical advantage with any of the specialized devices (eg, cutting balloon or directional or rotational atherectomy) for the treatment of ISR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/71\">",
"     71",
"    </a>",
"    ] and no change was made in the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/73\">",
"     73",
"    </a>",
"    ]. In comparison, the 2005 ESC task force for PCI concluded that the weight of evidence or opinion is in favor of efficacy of cutting balloon angioplasty for avoiding slipping-induced vessel trauma during PCI of ISR in conjunction with intracoronary brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Small vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the use of stents in smaller vessels is increasing, there is a paucity of data concerning the treatment of ISR in such vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Small coronary arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 73 patients, outcomes were assessed after the treatment of ISR of coronary arteries &le;2.85 mm in diameter using PTCA, excimer laser angioplasty, or restenting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/87\">",
"     87",
"    </a>",
"    ]. Although procedural success was 100 percent, 57 percent of patients had angiographic restenosis at six months, which was symptomatic in 34 percent. The rate of restenosis was greater with laser angioplasty compared to PTCA or restenting (78 versus 49 and 47 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in the treatment of in-stent stenosis is uncertain. Revascularization with CABG should be considered in patients who are deemed to not be candidates for percutaneous intervention or who meet the established criteria for its use in patients with stable angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H3#H3\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'CABG versus PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous intervention is preferred to CABG in most patients if the patient is a candidate for PCI. However, patient preference should be considered. The main advantage to CABG for ISR is the much lower rate of repeat revascularization, particularly with bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/88\">",
"     88",
"    </a>",
"    ]. The difference is much smaller with drug-eluting stents. However, this benefit must be weighed against the increased risk of stent thrombosis if dual antiplatelet therapy is prematurely discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link&amp;anchor=H6#H6\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'Drug-eluting stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H20#H20\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Late and one-year cumulative stent thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H12#H12\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Very late stent thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If CABG is performed in a patient with ISR, the long-term patency rate is significantly higher with an arterial graft (internal mammary or radial) compared to a saphenous vein graft [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/89\">",
"     89",
"    </a>",
"    ]. This finding is similar to that seen with CABG in other settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H2#H2\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Choice of graft'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of in-stent restenosis (ISR) and target lesion revascularization are much lower in the current era of drug-eluting stents (DES) compared to PTCA alone or with bare-metal stents (BMS). Nevertheless, symptomatic in-stent restenosis continues to be an important problem given the large numbers of patients receiving drug-eluting stents (",
"    <a class=\"graphic graphic_table graphicRef56696 \" href=\"UTD.htm?37/15/38140\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intravascular ultrasound (IVUS) should be used to evaluate the adequacy of stent placement, particularly after DES placement for restenosis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Predictors of restenosis in BMS'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In symptomatic patients with intracoronary BMS restenosis, we recommend repeat stenting using a DES, which is more effective than BMS, balloon angioplasty, and intracoronary radiation (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/46/24298/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Percutaneous coronary intervention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In symptomatic patients with intracoronary DES restenosis, there are insufficient data to suggest any specific treatment, although IVUS should be performed when possible to permit optimization of stent expansion. Repeat stenting with DES is performed in many centers. The use of a drug-eluting balloon is also a reasonable option, where available.",
"   </p>",
"   <p>",
"    Patient preference plays an important role in decision making at the time of symptomatic ISR. The relative benefits and risks of medical, percutaneous, and surgical treatments need to be discussed. In particular, the need for long-term dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and platelet P2Y12 receptor blocker) with DES must be understood by the patient.",
"   </p>",
"   <p>",
"    As in de novo treatment, the benefits of the use of DES for ISR must be weighed against the potential for stent thrombosis, which often leads to death or MI, if dual antiplatelet therapy is prematurely discontinued. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are unlikely to comply with a recommendation for long-term dual antiplatelet therapy, alternatives include continuation of medical therapy, balloon angioplasty or repeat bare-metal stenting, or CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27983762\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/1\">",
"      Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/2\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/3\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/4\">",
"      Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/5\">",
"      Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004; 110:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/6\">",
"      Kimura T, Morimoto T, Nakagawa Y, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012; 125:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/7\">",
"      Leon MB, Nikolsky E, Cutlip DE, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 2010; 3:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/8\">",
"      R&auml;ber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/9\">",
"      Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/10\">",
"      Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997; 95:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/11\">",
"      Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/12\">",
"      Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/13\">",
"      Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/14\">",
"      Chung IM, Gold HK, Schwartz SM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002; 40:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/15\">",
"      Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996; 334:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/16\">",
"      Asakura M, Ueda Y, Nanto S, et al. Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation 1998; 97:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/17\">",
"      Kuroda N, Kobayashi Y, Nameki M, et al. Intimal hyperplasia regression from 6 to 12 months after stenting. Am J Cardiol 2002; 89:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/18\">",
"      Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/19\">",
"      Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/20\">",
"      Kastrati A, Sch&ouml;mig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/21\">",
"      Goldberg SL, Loussararian A, De Gregorio J, et al. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol 2001; 37:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/22\">",
"      Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001; 38:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/23\">",
"      Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/24\">",
"      Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/25\">",
"      Prati F, Di Mario C, Moussa I, et al. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation 1999; 99:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/26\">",
"      Hoffmann R, Mintz GS, Mehran R, et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 1998; 31:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/27\">",
"      Serruys PW, Kay IP, Disco C, et al. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999; 34:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/28\">",
"      Gy&ouml;ngy&ouml;si M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000; 35:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/29\">",
"      Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation 2004; 109:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/30\">",
"      Mauri L, O'Malley AJ, Cutlip DE, et al. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 2004; 93:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/31\">",
"      Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005; 111:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/32\">",
"      Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005; 111:3435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/33\">",
"      Mauri L, Orav EJ, Candia SC, et al. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005; 112:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/34\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/35\">",
"      Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/36\">",
"      Cohen DJ, Doucet M, Cutlip DE, et al. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox? Circulation 2001; 104:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/37\">",
"      Hasdai D, Garratt KN, Grill DE, et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/38\">",
"      Violaris AG, Thury A, Regar E, et al. Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty. Heart 2000; 84:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/39\">",
"      Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/40\">",
"      Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/41\">",
"      Yoshitomi Y, Kojima S, Yano M, et al. Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J 2001; 142:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/42\">",
"      Castagna MT, Mintz GS, Leiboff BO, et al. The contribution of \"mechanical\" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J 2001; 142:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/43\">",
"      Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/44\">",
"      Kastrati A, Sch&ouml;mig A, Elezi S, et al. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999; 100:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/45\">",
"      de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 1999; 100:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/46\">",
"      Kastrati A, Sch&ouml;mig A, Elezi S, et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. Circulation 1998; 97:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/47\">",
"      Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/48\">",
"      Gruberg L, Weissman NJ, Waksman R, et al. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol 2002; 89:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/49\">",
"      Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/50\">",
"      Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/51\">",
"      Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/52\">",
"      Walters DL, Harding SA, Walsh CR, et al. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol 2002; 89:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/53\">",
"      Mishkel GJ, Moore AL, Markwell S, et al. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007; 49:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/54\">",
"      Fineschi M, Gori T, Pierli C, et al. Symptomatic failure after sirolimus-eluting stent implantation: a rare but challenging condition. Can J Cardiol 2007; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/55\">",
"      Mehran R, Mintz GS, Popma JJ, et al. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996; 78:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/56\">",
"      Baim DS, Levine MJ, Leon MB, et al. Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multicenter experience. The U.S. Palmaz-Schatz Stent Investigators. Am J Cardiol 1993; 71:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/57\">",
"      Eltchaninoff H, Koning R, Tron C, et al. Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol 1998; 32:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/58\">",
"      Bauters C, Banos JL, Van Belle E, et al. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation 1998; 97:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/59\">",
"      Alfonso F, Zueco J, Cequier A, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003; 42:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/60\">",
"      Alfonso F, Aug&eacute; JM, Zueco J, et al. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol 2005; 46:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/61\">",
"      Mehran R, Dangas G, Abizaid A, et al. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. Am Heart J 2001; 141:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/62\">",
"      Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/63\">",
"      Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003; 41:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/64\">",
"      Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/65\">",
"      Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005; 111:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/66\">",
"      Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/67\">",
"      Alfonso F, P&eacute;rez-Vizcayno MJ, Hernandez R, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006; 47:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/68\">",
"      Alfonso F, P&eacute;rez-Vizcayno MJ, Hern&aacute;ndez R, et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol 2008; 52:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/69\">",
"      Migliorini A, Shehu M, Carrabba N, et al. Predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis. Am J Cardiol 2005; 96:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/70\">",
"      Liistro F, Fineschi M, Grotti S, et al. Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. J Am Coll Cardiol 2010; 55:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/71\">",
"      Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/72\">",
"      Silber S, Albertsson P, Avil&eacute;s FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/73\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/74\">",
"      Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006; 295:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/75\">",
"      Ellis SG, O'Shaughnessy CD, Martin SL, et al. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J 2008; 29:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/76\">",
"      Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006; 295:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/77\">",
"      Mukherjee D, Moliterno DJ. Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. JAMA 2006; 295:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/78\">",
"      Lemos PA, van Mieghem CA, Arampatzis CA, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation 2004; 109:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/79\">",
"      Moussa ID, Moses JW, Kuntz RE, et al. The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). Am J Cardiol 2006; 97:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/80\">",
"      Cosgrave J, Melzi G, Biondi-Zoccai GG, et al. Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol 2006; 47:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/81\">",
"      Garg S, Smith K, Torguson R, et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 2007; 70:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/82\">",
"      Abe M, Kimura T, Morimoto T, et al. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation 2010; 122:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/83\">",
"      Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010; 55:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/84\">",
"      Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/85\">",
"      Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/86\">",
"      Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013; 381:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/87\">",
"      Gross CM, Kr&auml;mer J, Weing&auml;rtner O, et al. Clinical and angiographic outcome in patients with in-stent restenosis and repeat target lesion revascularisation in small coronary arteries. Heart 2000; 84:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/88\">",
"      Moustapha A, Assali AR, Sdringola S, et al. Percutaneous and surgical interventions for in-stent restenosis: long-term outcomes and effect of diabetes mellitus. J Am Coll Cardiol 2001; 37:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/89\">",
"      Gaudino M, Cellini C, Pragliola C, et al. Arterial versus venous bypass grafts in patients with in-stent restenosis. Circulation 2005; 112:I265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/46/24298/abstract/90\">",
"      Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49:616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1587 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-BFC6E11EC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24298=[""].join("\n");
var outline_f23_46_24298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1558346535\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE OF RESTENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1558346569\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patterns of restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREDICTORS OF RESTENOSIS IN BMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Angiographic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Late lumen loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Contact allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Strut thickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanical problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lesion morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intravascular ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stenting of multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84738363\">",
"      PREDICTORS IN DES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS OF IN-STENT RESTENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Indications for intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Repeat stenting in bare-metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Intracoronary radiation versus drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Treatment of drug-eluting stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Drug-coated balloon angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Specialized revascularization devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Small vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27983762\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1587|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/14/1262\" title=\"figure 1\">",
"      Predictors stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1587|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/39/11901\" title=\"table 1\">",
"      Coronary artery stents approved in the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/15/38140\" title=\"table 2\">",
"      Definitions and classification of stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/35/27196\" title=\"table 3\">",
"      Lesion-specific characteristics and outcome after balloon angiop",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34342?source=related_link\">",
"      Nickel hypersensitivity and coronary artery stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29081?source=related_link\">",
"      Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=related_link\">",
"      Use of intracoronary radiation to prevent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_46_24299="Screen quest adol firearm";
var content_f23_46_24299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Violence victims screening questions risk of adolescents carrying a firearm",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         <em>",
"          Fi",
"         </em>",
"        </strong>",
"        ghting",
"       </td>",
"       <td>",
"        During the last 12 months, have you been in a physical fight?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         <strong>",
"          G",
"         </strong>",
"        </em>",
"        ender",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         <strong>",
"          H",
"         </strong>",
"        </em>",
"        urt",
"       </td>",
"       <td>",
"        During the last 12 months, have you been in a fight in which you were injured and had to be treated by a physician or nurse?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         <strong>",
"          T",
"         </strong>",
"        </em>",
"        hreatened",
"       </td>",
"       <td>",
"        During the last 12 months, have you been threatened with a weapon (knife/gun) on school property?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         <strong>",
"          S",
"         </strong>",
"        </em>",
"        moker",
"       </td>",
"       <td>",
"        Have you ever smoked cigarettes regularly (1 cigarette/day for 30 days)?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hayes, DN, Sege, R. FiGHTS: A preliminary screening tool for adolescent firearms-carrying. Ann Emerg Med 2003; 42:798. Illustration used with permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24299=[""].join("\n");
var outline_f23_46_24299=null;
var title_f23_46_24300="Survival by number LNs examined";
var content_f23_46_24300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Impact of number of lymph nodes examined on survival in resected gastric cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of nodes examined",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        5-yr survival, percent (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        T1/2 N0",
"       </td>",
"       <td class=\"subtitle2\">",
"        T1/2 N1",
"       </td>",
"       <td class=\"subtitle2\">",
"        T3 N0",
"       </td>",
"       <td class=\"subtitle2\">",
"        T3 N1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1-9",
"       </td>",
"       <td>",
"        61 (57-66)",
"       </td>",
"       <td>",
"        33 (25-40)",
"       </td>",
"       <td>",
"        33 (29-37)",
"       </td>",
"       <td>",
"        14 (12-17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (n=560)",
"       </td>",
"       <td>",
"        (n=184)",
"       </td>",
"       <td>",
"        (n=528)",
"       </td>",
"       <td>",
"        (n=871)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        10-19",
"       </td>",
"       <td>",
"        67 (61-74)",
"       </td>",
"       <td>",
"        51 (41-61)",
"       </td>",
"       <td>",
"        50 (43-57)",
"       </td>",
"       <td>",
"        25 (20-29)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (n=269)",
"       </td>",
"       <td>",
"        (n=124)",
"       </td>",
"       <td>",
"        (n=261)",
"       </td>",
"       <td>",
"        (n=499)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        20-29",
"       </td>",
"       <td>",
"        71 (60-83)",
"       </td>",
"       <td>",
"        65 (50-80)",
"       </td>",
"       <td>",
"        56 (43-68)",
"       </td>",
"       <td>",
"        33 (24-42)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (n=49)",
"       </td>",
"       <td>",
"        (n=31)",
"       </td>",
"       <td>",
"        (n=47)",
"       </td>",
"       <td>",
"        (n=88)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        30-39",
"       </td>",
"       <td>",
"        87 (74-100)",
"       </td>",
"       <td>",
"        25 (0-67)",
"       </td>",
"       <td>",
"        58 (37-79)",
"       </td>",
"       <td>",
"        42 (26-57)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (n=61)",
"       </td>",
"       <td>",
"        (n=4)",
"       </td>",
"       <td>",
"        (n=58)",
"       </td>",
"       <td>",
"        (n=92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        40+",
"       </td>",
"       <td>",
"        93 (79-100)",
"       </td>",
"       <td>",
"        70 (41-99)",
"       </td>",
"       <td>",
"        83 (62-100)",
"       </td>",
"       <td>",
"        50 (30-70)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (n=14)",
"       </td>",
"       <td>",
"        (n=11)",
"       </td>",
"       <td>",
"        (n=14)",
"       </td>",
"       <td>",
"        (n=28)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Smith, DD, et al. J Clin Oncol 2005; 23:7114.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24300=[""].join("\n");
var outline_f23_46_24300=null;
var title_f23_46_24301="Aminophylline B agonist asthma";
var content_f23_46_24301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lack of efficacy of aminophylline in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Change in FEV",
"    <sub>",
"     1",
"    </sub>",
"    in 20 patients treated with both intravenous aminophylline and inhaled metaproterenol (blue squares) and in 20 patients treated with inhaled metaproterenol alone (red triangles). There was no added benefit from aminophylline.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Siegel D, Sheppard D, Gelb A, Weinberg PF. Am Rev Respir Dis 1985; 132:283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24301=[""].join("\n");
var outline_f23_46_24301=null;
var title_f23_46_24302="Glenohumeral osteoarthritis";
var content_f23_46_24302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glenohumeral osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain x-ray is from a 67-year-old woman with anterolateral shoulder pain and stiffness for several years. She denies any history of fracture, dislocation, or severe injury. However, she states: \"People say I've always done man's work. It doesn't surprise me that it is arthritic since arthritis runs in my family.\"&nbsp;On plain&nbsp;x-ray,&nbsp;glenohumeral osteoarthritis is characterized by loss of articular cartilage between the humeral head and the glenoid, osteophyte formation extending from the inferior portion of the humeral head, and humeral head sclerosis. The combination of the loss of cartilage and the osteophyte creates the club-like deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24302=[""].join("\n");
var outline_f23_46_24302=null;
var title_f23_46_24303="Hereditary nephritis IF";
var content_f23_46_24303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diminished anti-GBM antibody binding in hereditary nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Indirect immunofluorescence microscopy with anti-glomerular basement membrane antibodies shows extensive binding to a normal glomerulus (left panel), but minimal binding to a glomerulus from a patient with hereditary nephritis (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_46_24303=[""].join("\n");
var outline_f23_46_24303=null;
